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 Asymmetric synthesis with biocatalyst has become an increasingly interesting and 
cost effective manufacturing process in fine chemicals, pharmaceuticals, and 
agrochemical intermediates. Enoate reductases from the Old Yellow Enzyme family offer 
high substrate efficiency, region, stereo-, and enantioselectivity in the catalyzed 
biotransformations. Asymmetric reduction of activated C=C bond is one of the most 
widely applied synthetic tools for the potential to generate up to two stereogenic centers 
in one step reaction. Current existing synthetic methods of asymmetric hydrogenation 
involve the use of precious metals in conjunction with chiral phosphines as well as 
organocatalytic hydrogenation of cyclic enones to allow a wider choice of substrates and 
products. However, the addition of biocatalytic hydrogenation of activated alkenes 
proved to be highly effective to produce enantiomerically pure compounds and become a 
precious addition tools for both the established synthetic pathways and novel methods.    
 The thesis contributed to the development and characterization of the Old Yellow 
Enzyme family with regards to addition of new chemistry such as exploitation of 
nitroreductase activity with NRSal from Salmonella typhimurium, where we investigated 
the reduction of α,β-unsaturated carbonyl compounds, nitroalkenes, and nitroaromatics 
substrates, and also reported the first single-isolated enzyme-catalyzed reduction of 
nitrobenzene to aniline through the formation of nitrosobenzene and 
phenylhydroxylamine as intermediates. The development and characterization of novel 
enzymes YersER from Yersinia bercoviei and KYE1 from Kluyveromyces lactis showed 
both enzymes have broad enoate reductase specificity and able to operate under broad 
temperature and pH optima but different specificity patterns. Both substrate- and enzyme-
based stereocontrol were also observed for both YersER and KYE1 to furnish opposite 
stereoisomeric products. Further improvement and characterization on XenA from 
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Pseudomonas putida showed broad catalytic activity and reduces various α,β-unsaturated 
and nitro compounds with moderate to excellent stereoselectivity. Mutations of XenA 
C25G and C25V are able to reduce nitrobenzene, a non-active substrate for the wild type, 
to produce aniline. The combination of computational protein engineering in form of the  
Principal Component Analysis method together with structure-guided consensus enabled 
the improvement of YersER, where significant improvements of specific activity were 
detected. Lastly, the work also contributed towards larger-scale system preparation by 
looking into enzyme stability and organic solvent behavior. We studied the total turnover 
number (TTN) as an indicator of lifetime biocatalyst productivity for YersER, KYE1, and 
XenA. The TTN of XenA proved to be dominated by chemical rather than thermal 
instability. Also, the effects of organic solvents on enzyme activity and stereoselectivity 
were tested with YersER and KYE1 to show the sustainable bioreduction efficiency even 
at high organic solvent content. Future work will focus to enable sustainable and stable 
scale-up system to demonstrate the possible applications of these enzymes. 
In summary, the increasing knowledge about this Old Yellow Enzyme family 
together with recent advances in biotechnology renders the enoate reductases a tool of 
choice for industrial applications. Detailed understanding of the knowledge of Old 
Yellow Enzyme substrate specificity and stereoselectivity, combined with structural and 
computational modeling techniques enable the future development and improvement of 








 Enzymes are a class of macromolecules with the ability to bind small molecules 
and to affect the rate of reaction. Like all other catalystsle, enzymes lower the activation 
energy and dramatically increase the rate of a reaction. In an enzyme reaction, initial free 
enzyme (E) and free substrate (S) combine reversibly to form an enzyme-substrate (ES) 
complex. The ES complex passes through another transition state to form enzyme-
product (EP) complex, which then dissociate into free enzyme and free product (P) (Fig 
1.1). Based on the proposed model, Leonor Michaelis and Maud Menten derived the first 









Figure 1.1. Uncatalyzed reaction versus enzyme-catalyzed reaction. 
  
 Over the past 20 years, biocatalysis emerged as key toolbox in the industrial 
synthesis of bulk chemicals, agrochemical intermediates, pharmaceuticals intermediates, 
active pharmaceuticals, and food ingredients.  Advancements in novel enzyme discovery 
with recombinant DNA technology allowed for the development of more efficient and 
robust enzyme systems and improved the productivity and simplicity of biocatalytic 













Uncatalyzed Enzyme catalyzed 
E = enzyme, S = substrate, [ES] = enzyme-substrate 
complex, P = product, ≠ = transition state, ∆G = free 
enthalpy. Ea = activation energy 
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to noncatalyzed reactions. (ii) Biocatalysis are environmental benign reagents that enable 
the sustainable development of green chemistry processes in industry. Environmental 
benign manufacturing processes help to prevent the depletion of non-renewable resources 
and reduce the production of hazardous substances. Also, since biocatalysis operates 
under mild reaction condition in the range around pH 5 - 10 and temperature of 20 – 50 
o
C, it also minimizes undesired side reactions (decomposition, isomerization, 
racemization, and rearrangements) that often occur in traditional chemical processes. (iii) 
High selectivity of enzymes often increases the chemo-, regio-, and enantio- selectivity of 
a reaction. This is especially important for synthesis of bioactive enantiomers such as 
pharmaceuticals or agrochemicals, which often required high enantiopurity to avoid 
unwanted side effects by the opposite enantiomer product.[1, 2] 
 Today, the biggest role for biocatalysis applications lies in the pharmaceutical 
sectors due to its exquisite region- and stereo- selectivities. Chiral pharmaceutical 
reagents have continuously received particular attention due to the human body functions 
using chiral catalysis. Survey showed that in 2000, 35% of the pharmaceutical 
intermediates were chiral and this number is expected to increase to 70% by 2010. The 
increasing complexity of the molecules that require multiple chiral centers further favor 
the development of biocatalytic steps in replacement of difficult chemical synthesis. 
Although the majority of pharmaceutical processes feature relatively small production 
volumes (10 – 10000 tons per annum) compared to chemical processes, there are few 
constraints for biocatalytic process to be economically viable. Process intensity for a 
biocatalytic process needs to be comparable to chemical processes with product 
concentration of at least 50 - 100 g/l and sufficient yield in gram product per gram 
catalyst used. Efficient process development will require integration of various 
disciplines including chemistry, enzymology, engineering, molecular biology, and 
microbiology. New techniques such as process miniaturization and mathematical 
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modeling are often exercised during the scale-up period for rapid process testing. All 
these advancements continuously improve the capability of biocatalysis to reach its full 
potential in pharmaceutical synthesis and become a promising area of research for both 
academia and the industrial community.[4-6]    
 
1.1 “Old Yellow Enzyme” Family and Enoate Reductases 
Flavoenzymes are a group of oxidoreductases enzymes that catalyzes a wide 
range of biochemical reactions ranging from dehydrogenation of metabolites, one- and 
two-electron transfer redox reactions, oxygen activation during oxidation and 
hydroxylation reactions, and light emission in bioluminescent bacteria. Flavin was first 
discovered around 1890s by Wynter Blyth, an English chemist, as a bright yellow 
pigment isolated from cow‟s milk. The isolated molecule was later known as riboflavin, 
or also known as vitamin B2.[7-9]
 
The flavoenzyme family consists of flavin adenine 
dinucleotide (FAD)-dependent and flavin mononucleotide (FMN)-dependent proteins, 
which both contain a unique tricyclic heteronuclear isoalloxazine ring system as 
coenzyme and frequently possess (αβ)8 TIM barrel folding structure (Fig 1.2). The 
reactive site of flavin lies in the tricyclic isoalloxazine ring system. The N1-C2=O2 locus 
was reported to have close contact (< 3.5 Ǻ) with positively charged side chains such as 
Lys or Arg. The positive charges at this position will stabilize anionic form of reduced 
flavin and favor protein binding by increasing the cofactor‟s redox potential. The N5 
locus was reported to responsible for substrate binding. In most flavoproteins, N5 is 
within hydrogen-bond distance (~ 3 Ǻ) from a hydrogen donor, which allows the 




Figure 1.2. Structure of riboflavin, FMN, and FAD. 
 
Old yellow enzyme (OYE) is a subfamily of flavor enzymes that catalyze 
stereoselective reduction of activated C=C bonds in the presence of nicotinamide 
cofactor. Old Yellow Enzyme (OYE, EC 1.6.99.1) was first discovered in 1933 by 
Christian and Warburg during their investigation on biological oxidations. It was isolated 
from brewers‟ bottom yeast and identified as the first flavin-dependent enzyme [10]. 
Since then, OYE from Saccharomyces carlsbergensis has given rise to an ever growing 
family of enzymes sharing similar characteristics but displaying variable reactivity, and 
that have been found among yeasts, bacteria, higher plants [11, 12] and most surprisingly 
in parasites [13]. An OYE homolog was identified in a non-yeast organism for the first 
time in 1979, in the cytosol fraction of Gluconobacter suboxydans [14]. Since then, 
multiple homologs have been discovered, identified, and characterized. Members of this 
family of flavoproteins so far include OYE from Saccharomyces carlsbergensis [15], 
OYE2-3 from Saccharomyces cerevisiae, KYE1 from Kluyveromyces lactis [16-18], 
OYE from Candida macedoniensis [19], trans-2-enoyl-coenzyme A reductase and N-
ethlymaleimide reductase (NemA) from Escherichia coli [20-22], estrogen-binding 
protein (EBP1) from Candida albicans [23], YqjM from Bacillus subtilis [24], NCR from 
Zymomonas mobilis [25], SYE1-4 from Shewanella oneidensis [26], Yers-ER from 
Yersinia bercovieri [17], morphinone reductase from Pseudomonas putida M10 [27], 
pentaerythritol tetranitrate (PETN) reductase from Enterobacter cloacae PB2 [28], 
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xenobiotic reductases XenA from Pseudomonas putida II-B and XenB from 
Pseudomonas fluorescens I-C resp. [29, 30], glycerol trinitrate reductase (NerA) from 
Agrobacterium radiobacter [31], 12-oxophytodienoate reductases OPR1-3 from 
Arabidopsis thaliana and Lycopersicon esculentum [32, 33], as well as OPRs from pea, 
maize and rice [34-37]. Enoate reductase activity has also been detected in a number of 
additional microorganisms and plants: Aspergillus niger [38, 39], Rhodotorula rubra 
[40], Burkholderia sp. WS [41], Catharanthus roseus [42], Nicotiana tabacum [43], 
Peptostreptococcus productus [44], Synechococcus sp. [45], Glycine max [46], Astasia 
longa [47], Marchantia polymorpha [48], Acetobacterium woodii [49, 50] and more [51, 
52]; but most of the corresponding enzymes have not been identified yet (in the case of 
Glycine max, Astasia longa and Nicotiana tabacum, purified enzymes were described as 
enone reductases [46, 47, 53, 54]). A phylogenetic tree of the OYE family shows the 





Figure 1.3. Phylogenetic tree of OYE family (constructed using ClustalW2 [55]). The 
names of the proteins are indicated to the right of the tree with the UniProtKB Accession 
Nos. given in parentheses (clustering NJ method used). 
 
The use of OYE as a reducing agent was first demonstrated by Warburg while he 
was investigating the reaction between glucose-6-phosphate, NADP
+
, an enzyme 
(“Zwischenferment”), and a substance called “Gelbe Ferment”, later identified as OYE 
and permitting the system to form a complete respiratory chain reacting with molecular 
oxygen [56]. Theorell showed much later that the yellow color was due to flavin 
mononucleotide (FMN) [57]. 
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Extensive studies have been conducted since then in an attempt to identify the 
physiological function of OYE, all rather inconclusive, but a general consensus arose on 
the likely role of OYE in oxidative stress response [26, 58]. Furthermore, the enzyme 
demonstrated the ability to reduce different types of substrate, most notably C=C bonds 
(Fig 1.4) [7, 59, 60], but also more complex compounds such as nitrate esters and nitro 
aromatic molecules [61-65]. The reaction mechanism for the reduction of -unsaturated 
compounds has been extensively studied, however, less is known about mechanistic 




Figure 1.4. Asymmetric bioreduction of activated alkenes bearing an electron-





At the time when studies on OYE were starting to give insight in this new 
chemistry, Simon et al. published their work on enoate reductases (EC 1.3.1.31) from 
anaerobic Clostridium species (Clostridium kluyveri, Clostridium tyrobutyricum and 
Clostridium sporogenes) catalyzing the reduction of carbon-carbon double bond of -
unsaturated carboxylate anions (hence the nomenclature) [66, 67]. However, despite 
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sequence similarities, these enzymes differ from the OYE family as they are iron-sulfur 
NADH-dependent flavoproteins [68, 69]. They have been shown to catalyze the 
reduction of carbon-carbon double bonds of (weakly activated) 2-enoates as well as of 
-unsaturated aldehydes, cyclic ketones, methylketones and recently -disubstituted 
aromatic nitroalkenes [70, 71]. 
 
 
1.2 Reactions catalyzed by enoate reductases 
Members of the „Old Yellow Enzyme‟ family share common catalytic properties 
as they are able to reduce a variety of different substrates such as nitro esters, nitro 
aromatics, and -unsaturated compounds (activated by an electron withdrawing group 
such as aldehyde, ketone, imide, nitro, nitrile, carboxylic acid or ester) at the expense of a 
nicotinamide cofactor (Fig 1.4, Fig 1.5) [12, 72-74]. The physiological oxidant of OYE 
has not been clearly identified yet but common electron acceptors include molecular 
oxygen, methylene blue, cyanides, quinones, and the olefinic bond of α,β-unsaturated 
carbonyl and carboxylic compounds [59]. OYE characteristically interacts with phenolic 
compounds to yield long wavelength charge transfer bands in the region of 500-800 nm, 
which were attributed to the formation of OYE-phenolate complex [7, 75]. 
 
1.2.1 Asymmetric reduction of carbon carbon double and triple bonds 
The asymmetric bioreduction of C=C bonds using enoate reductases was initially 
performed using whole cell fermentation with baker‟s yeast [76, 77]. However, the whole 
cell reactions were generally impeded by the presence of endogeneous ketoreductases in 
the host cells, which also require the same nicotinamide cofactor for bioreduction of C=O 
bonds. The competing reduction of C=C- and C=O- bonds by enoate reductases and 
alcohol dehydrogenases often resulted in poor chemoselectivity in the overall reaction 
and produced the corresponding alcohols of the saturated products [78]. In the case of 
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conjugated enals, the prim-alcohol dehydrogenases often over-reduced the substrate to 
the corresponding prim-alcohols [51, 52]. This competing side reaction was less observed 
in the case of conjugated enones as the reduction of ketone by sec-alcohol 
dehydrogenases is slower compared to the enoate reductase activity [12, 79]. 
 
Figure 1.5. Asymmetric bioreduction of α,β-unsaturated carbonyl compounds (aldehydes 
and ketones),  α,β-unsaturated carboxylic acids, imides and ynones [12, 80]. 
 
Besides the asymmetric bioreduction of C=C bonds, OYE also showed ability to 
reduce C-C triple bonds, converting ynones to -saturated ketones via the formation of 
the intermediate enones. OYE1-3 from yeast catalyzed the reduction of 4-phenyl-3-
butyne-2-one to (E)-4-phenyl-3-butene-2-one (only the trans isomer was produced), and 
subsequently produced 4-phenyl-2-butanone in the presence of NAD(P)H [80]. OYE was 
also shown to promote aromatization of α,β-unsaturated cyclic enones such as 2-
cyclohexenone and 3-oxodecalin-4-ene. The aromatization of cyclic enones follows the 
trans-dehydrogenation of the 1β,2α-hydrogens, and is accompanied by a dismutation 
10 
 
reaction in which the olefinic bond of a second molecule of each substrate is reduced to 
give the saturated cyclic ketone [59]. The energetically favorable product aromatization 
drives the desaturation. Thus, two molecules of 2-cyclohexenone yielded one molecule of 
phenol and cyclohexane each (Fig. 1.6). The desaturation of cyclohexanone into 
cyclohexenone and further into phenol was recently reported using an OYE homolog 
from Geobacillus kaustophilus. Similarly, the enzyme was shown to introduce C-C 
double bonds adjacent to carbonyl groups in compounds such as dihydrocarvone 
(yielding carvone) and testosterone (yielding boldenone). 
 
 
Figure 1.6. Dismutation reaction of cyclohexenone catalyzed by OYE. Adapted from [16, 
59]. 
 
α,β-Unsaturated carboxylic acids and derivatives such as esters, lactones, cyclic 
anhydrides, and imides are also good substrates for enoate reductases [12, 60, 81]. The 
overall bioreduction also showed excellent stereoselectivities. In the case of substrates 
bearing two cumulated C=C double bonds, OYE only reduced the targeted α,β-bond, but 
not the γ-bond [82]. Lactones were also shown to be reduced efficiently with baker‟s 
yeast with high stereoselectivities [83]. Acid anhydrides and imides were also reported to 
be good substrates for enoate reductases. N-phenyl-2-methylmaleimide was reduced 
completely by isolated enzymes of OYE1-3 from yeast in the presence of NAD(P)H [60]. 
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Controlling the stereochemical outcome of the reduction of -unsaturated compounds 
can be achieved via substrate- and/or enzyme-based stereocontrol (Fig. 1.7). The 
reduction of (E)- and (Z)-enoates and enals to opposite enantiomers constitutes an 
example of substrate-based stereocontrol. The R/S- configuration of the reduced products 
were shown to depend on the E/Z-configuration of the original substrates, as observed in 
the reduction of methyl 2-chloro-2-alkenoates by fermentation with baker‟s yeast (the 
actual substrates were the corresponding acid forms obtained after hydrolysis of the esters 
by unspecific esterases) [84]. The same effect was observed in the reduction of citral with 
OYE1 [25]. Furthermore, whereas one isomer can be accepted by OYEs, the oppositely 
configured substrate is not, leading to dramatic substrate recognition, as observed with 
citraconic acid and its Z-configured analog mesaconic acid, with OPR1 and YqjM. Their 
corresponding esters, however, were both accepted but led to strictly opposite 
enantiomers upon reduction with YqjM [85]. On the contrary, the reduction of (E)- and 
(Z)-isomers of various nitroolefins proceeded in a stereoconvergent manner using PETN 
reductase from Enterobacter cloacae PB2 [86]. 
Another possibility to control the enantiopurity of the product is to use different 
enzymes (enzyme-based stereocontrol). The most striking example was reported with two 
isozymes from Lycopersicon esculentum, OPR1 and OPR3. Despite high sequence 
identity, their stereoselectivities were opposite in the reduction of 1-nitro-2-
phenylpropene and this striking result was explained by subtle changes in the active site 







Figure 1.7. Examples of stereocontrol in the reduction of C=C bonds using OYE 
homologs (reduction of methyl 2-chloro-2-alkenoates proceeded at the acid stage, 
therefore diazomethane was used to recover the ester form after reduction with baker‟s 





1.2.2 Bioreduction of nitro compounds 
Over the last few years, there has been significant development in the 
biodegradation and mineralization of explosives from the two world wars [89-91]. The 
main enzymes involved are nitroreductases, which reduce a wide range of aromatic nitro 
compounds such as nitrofurazones, nitrobenzenes, nitrophenols, and various explosives 
including trinitrotoluene (TNT) and pentaerythritol tetranitrate (PETN), as well as nitrate 
esters such as glycerin trinitrate (GTN). Nitroreductases have been grouped into two 
subfamilies according to their mechanism: oxygen-insensitive type I nitroreductase and 
oxygen-sensitive type II nitroreductase. Most nitroreductases were identified in bacterial 
strains, such as NfsA and NfsB from E. coli [92], SnrA and Cnr from Salmonella enterica 
serovar Typhimurium [93] or PnrA and PnrB from Pseudomonas putida [94]. Similarly 
to OYE, those nitroreductases contain FMN as the coenzyme and require NAD(P)H as 
physiological reductant [95]. 
The OYE family is also known for its nitroreductase activity on explosives such 
as PETN and TNT. Several well characterized members of the OYE family displaying 
nitroreductase activity include for instance XenA and XenB from Pseudomonas sp. [29], 
PETN reductase from Enterobacter cloacae [96], NemA from E. coli [97], morphinone 
reductase from Pseudomonas putida M10 [27], OYEs from Saccharomyces sp. [98] and 
YqjM from Bacillus subtilis [24]. PETN reductase, for example, was shown to be able to 
grow on TNT as nitrogen source and converted TNT to yield monohydride- 
Meisenheimer complex (H
-
-TNT) and dihydride-Meisenheimer complex (2H
-
-TNT, Fig. 
1.8) [99], which was shown to release nitrite upon rearomatization to 2-hydroxylamino-6-
nitrotoluene in a slow abiotic process [100]. These reactions correspond to two different 
types of aromatic nitroreduction: reducing activity involving the reduction of the nitro 
group of TNT leading to hydroxylaminodinitrotoluene via the nitroso intermediate, 
possibly followed by further reduction to the corresponding amine, and reducing activity 
involving the reduction of the aromatic ring by the OYE to produce the corresponding 
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Meisenheimer complex, ultimately followed by the liberation of nitrite (recently 
described as type I, resp. type II hydride transferase [61, 62], despite the fact that 
transferases are not reductases). All enzymes of the OYE family are able to perform 
reduction of the nitro group, while the reduction of the aromatic ring is only catalyzed by 
PETN reductase, XenB, and NemA with the formation of H
-
-TNT followed by 2H
-
-TNT 
[101]. The dimerization of the Meisenheimer dihydride complex with 
hydroxylaminodinitrotoluenes was recently reported for enzymes displaying both types 
of reducing activity, leading to secondary diarylamines [61, 102]. 
Nitrate esters such as GTN or PETN were also reported to be reduced by the OYE 
family, via the cleavage of the ester bond leading to the liberation of nitrite and the 
formation of the corresponding alcohol. XenA and XenB, PETN reductase, NerA, and 
OYEs have all been shown to catalyze the reduction of GTN in the presence of NAD(P)H 
[103]. 1-2 mol of nitrite is removed from GTN while 2 mol of nitrite are usually removed 
from PETN during the reaction [28, 98, 104]. Several other organic nitroesters with 
explosives properties were also reduced by PETN reductase, with kinetic parameters 
depending on their log Pow values (generally, the higher the log Pow value, the higher the 




Figure 1.8. Reduction of nitro compounds by OYE family: (1) Reduction of nitroester 
(GTN) with liberation of nitrite, (2a) Reduction of the nitro group of TNT to the 
corresponding aromatic amine, (2b) Reduction of the aromatic ring of TNT to the 
corresponding hydroxylamino product via Meisenheimer complex formation, (3) 
Asymmetric reduction of nitroalkenes to nitroalkanes (* chiral center) [62, 87, 98, 100]. 
 
Besides, several other members of OYE family are also capable of catalyzing the 
hydrogenation of 1-nitrocyclohexene. The enzymes first catalyze the formation of 
nitronate as intermediate, followed by protonation of the nitronate toward the 
corresponding nitrocyclohexane (Fig. 1.9) [101]. Meah and Massey demonstrated the 
possibility to accumulate nitronate with a single mutant of OYE (Y196F), providing a 




Figure 1.9. OYE-catalyzed reduction of nitrocyclohexene and formation of nitronate. 
Adapted from [106]. 
 
Last, the asymmetric bioreduction of aliphatic nitroalkenes does not affect the 
nitro group, rather it affords the chemoselective reduction of the C=C bond. Such activity 
was observed with OYE1-3 from yeast, OPR1 and OPR3 from Lycopersicon esculentum, 
YqjM from Bacillus subtilis, NCR reductase from Zymomonas mobilis, PETN reductase 
from Enterobacter cloacae PB2 and whole cells of Clostridium sporogenes, which all 
demonstrated excellent activities along with great stereoselectivities [60, 71, 74, 81, 86]. 
Recently, PETN reductase was shown to display activity on nitrogen analogues from 
organic nitrates (N-nitramines), e.g. RDX (hexahydro-1,3,5-trinitro-1,3,5-triazine) and 
HMX (octahydro-1,3,5,7-tetranitro-1,3,5,7-tetrazocine). However, reactivity on those 
compounds was three orders of magnitude lower than that on aliphatic nitroesters [105]. 
 
 
1.3 Biochemistry of Old Yellow Enzyme 
1.3.1. Mechanism and structure 
The asymmetric reduction of activated C=C bonds using members of the „Old 
Yellow Enzyme‟ family resembles a trans Michael addition of [2H]. The mechanism 
17 
 
involved was studied extensively and good understanding on the molecular level has been 
reached [16, 107-109]. Besides, the access to a number of crystal structures (including 
those of enzymes complexed with various types of ligand [110-116]), together with 
mutational studies, allowed the identification of crucial (and conserved) residues. 
The reaction occurs via a Ping Pong Bi Bi mechanism, where the flavin coenzyme 
is reduced by NAD(P)H via the transfer of the 4-pro-R hydridic hydrogen [59] in what is 
described as the „reductive half-reaction‟. A hydride is then transferred from the reduced 
flavin (from the N5 atom) onto the C of the activated -unsaturated substrate 
(„oxidative half-reaction‟) followed by the addition of a proton on the C from the other 
side of the substrate. The reaction is thus strictly trans-specific, differing from its pure 
synthetic equivalent in homogeneous catalysis (cis-hydrogenation using transition metal-
based catalysts [117-119]). As the prosthetic group is re-oxidized during the oxidative 
half-reaction (completion of catalytic turnover), the enzyme is ready for another cycle, 
provided sufficient amount of nicotinamide cofactor is present. 
OYE is a dimer of ~45 kDa subunits with one non-covalently bound FMN per 
subunit. It folds into a single domain based on a TIM barrel (()8 barrel) with the FMN 
binding within the barrel near the carboxy-terminal ends of the -strands [112] (Fig. 
1.10). Fitzpatrick et al. classified YqjM as the first representative of a new bacterial 
subfamily of OYE homologs based on structural differences with OYE [24]. This is of 
special relevance as structure impacts activity and therefore would also affect subsequent 





Figure 1.10. Ribbon diagram of the structure of OYE with FMN cofactor (deposited as 
1oya in the Protein Databank. PDB: http://www.rcsb.org/ [112]). 
 
The residues involved in substrate binding were identified in OYE as H191 and 
N194, and are conserved along the family (N194 is replaced by H in some cases), 
hydrogen bonding with the activating group (e.g. carbonyl). Interestingly, H184N 
mutation in PETN reductase (equivalent to OYE N194) prevented the hydride addition 
onto the aromatic ring of TNT, whereas H
-
-TNT was still a substrate for the mutant. This 
led to the conclusion that H/N184 might be crucial in determining the fate of TNT, i.e. 
aromatic ring-reduction vs. nitro-reduction (cf. section 2.2) [101]. Y196, positioned as an 
active site acid, was shown to be the proton donor in OYE [107], and is also conserved. 
This residue is replaced by C191 in morphinone reductase and was shown not to be 
crucial for reduction of olefinic bonds; in this specific case, the proton was inferred to be 
coming from the solvent [110, 120]. Similarly, Y186 was shown not to be a key proton 
donor in the reduction of -unsaturated carbonyl compounds by PETN reductase [121]. 
Depicted in Figure 1.11 is a sequence alignment of residues 164-221 of OYE and its 
homologs, including the substrate binding site (H191 and N194) and the active site acid 
(Y196). In the NerA-catalyzed reduction of GTN, Y183 (equivalent to OYE Y196) was 
shown to play a role in substrate binding, whereas N181 (equivalent to N194 in OYE) 
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and a second N238 that lies close to Y183 (equivalent to Y196 in OYE) in the NerA 
model structure may influence substrate specificity [31]. 
 
 
Figure 1.11. Partial amino acid sequence alignment of members of the OYE family 
(generated using ClustalW2 [55]). PDB Accession Nos. are a follows:  Q02899 for OYE1 
from Saccharomyces carlsbergensis; Q03558 for OYE2 from Saccharomyces cerevisiae; 
P41816 for OYE3 from Saccharomyces cerevisiae; P40952 for KYE1 from 
Kluyveromyces lactis; P43084 for EBP1 from Candida albicans; Q5NLA1 for NCR from 
Zymomonas mobilis; Q9RPM1 for XenB from Pseudomonas fluorescens; P77258 for 
NemA from Escherichia coli; P71278 for PETN reductase from Enterobacter cloacae; 
Q51990 for morphinone reductase from Pseudomonas putida; O31246 for GTN 
reductase from Agrobacterium tumefaciens (NerA); Q8LAH7 for OPR1 from 
Arabidopsis thaliana; Q9XG54 for OPR1 from Lycopersicon esculentum; Q9FUP0 for 
OPR3 from Arabidopsis thaliana; Q9FEW9 for OPR3 from Lycopersicon esculentum; 
P54550 for YqjM from Bacillus subtilis; Q9R9V9 for XenA from Pseudomonas putida 
(H191, N194 and Y196 from OYE1 from Saccharomyces carlsbergensis and equivalents 
are highlighted in boxes). 
 
The nature of the physiological reductant cannot be generalized across the OYE 
flavoproteins. Whereas NADPH is considered as OYE favored cofactor, morphinone 
reductase clearly shows a strong preference for NADH (NADPH/NADH ratio of 0.2 vs 
10, resp. [101]), as does NerA (specific activity 11-fold lower for NADPH) [65], while 
OYE from Candida macedoniensis does not differentiate between the two nicotinamide 
forms [19] and the four SYEs of Shewanella oneidensis display different cofactor 
preferences [26]. In recent conversion studies, a number of OYEs showed ability to 
convert various substrates similarly fast, independently from the cofactor [60, 81]. Since 
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the reactions were run over extended periods of time, an analogy could be drawn with 
thermodynamic vs. kinetic reaction control. Cofactor specificity was also shown to be 
dependent on the substrate [17]. 
Massey et al. proposed to classify an enzyme as an OYE homolog under the 
condition that it contains FMN as coenzyme, shows NADPH oxidase activity and 
furthermore shares similar spectral properties, i.e. phenol binding leading to the 
formation of characteristic absorption changes [16]. The development of charge transfer, 
however, has not been reported for all the suspected members of the OYE family, which 
would thus result in a reorganization of the OYE family [14] (changes in absorption 
spectrum obtained on complex formation between Old Yellow Enzyme and phenolic 
compounds such as p-hydroxybenzaldehyde were shown to arise due to charge-transfer 
interactions [122]). 
Enoate reductases from anaerobic Clostridia, despite sharing identical activities 
with members of the OYE family (reduction of the C=C bond in -unsaturated 
compounds), belong to a different class of enzymes. Enoate reductase from C. 
tyrobutyricum, for instance, is a homododecamer with each subunit comprising a Fe4S4 
cluster as well as one molecule each of FMN and FAD. These enzymes catalyze the 
transfer of the pro-S hydrogen from NADPH to the -position of the substrate in contrast 
to OYEs [70, 123, 124], and also operate in a strictly trans stereospecific fashion [125]. 
 
 
1.3.2. Physiological role 
The identification of one single physiological role within the whole family of 
OYE could not be achieved so far. One certainty concerns OPRs, where the enzymes are 
involved in the biosynthesis of jasmonic acid, by reducing the 10,11-double bond of 12-
oxophytodienoic acid (OPDA) to 3-oxo-2-(2'-pentenyl)cyclopentaneoctanoic acid (OPC-
8:0), a precursor of this plant hormone. Surprisingly, only OPR3 isoforms (both from 
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Arabidopsis thaliana and Lycopersicon esculentum) are involved in the synthesis of 
jasmonate. They accept (9S,13S)-OPDA as a substrate and yield (9S,13S)-OPC-8:0, the 
precursor of the biologically active jasmonate isomer, whereas other isoenzymes are 
strictly specific for the (9R,13R)-enantiomer (Fig. 1.12) [33, 126, 127]. Morphinone 
reductase was shown to be involved in the metabolism of morphine and codeine, by 
reducing morphinone and codeinone to hydromorphone (dihydromorphinone) and 
hydrocodone (dihydrocodeinone), respectively [27, 128]. Implication in the metabolism 
of unsaturated fatty acids has been also proposed for trans-2-enoyl-CoA reductase of 
Escherichia coli [22, 129]. Overall, OYEs are often linked to oxidative stress response 
and modulation [26, 58]. It was suggested that natural physiological substrates may be 
lipid peroxidation breakdown products often toxic for cells [107, 130]. Recently, OYE3 
was indeed proven to be linked with Bax-induced lipid peroxidation [131]. Also, OYE2 
was shown to protect against small reactive -unsaturated carbonyl compounds such as 
acrolein (a major breakdown product of lipid peroxidation process), in vivo [132]. 
Furthermore, OYE was suggested to control the redox state of actin (thereby maintaining 
the proper plasticity of the actin cytoskeleton and protecting it from oxidative stress) and 
be involved in programmed cell death processes (apoptosis) [133, 134]. Besides, 
investigations on SYE1-4 from Shewanella oneidensis suggested multiple physiological 
roles existing for the different OYE homologs within a single organism [26]. 
Combining those findings with the wide substrate spectrum of OYEs and their 
xenobiotic reductase activity, an implication of OYEs in antioxidant defense system and 





Figure 1.12. 12-Oxophytodienoic acid stereoisomers. Only (9S,13S)-isomer leads to 
biologically active jasmonic acid by OPR3 [126]. 
 
1.4 Biotechnological Applications 
1.4.1. Whole cell systems 
The use of whole cell systems has dominated the field of biocatalysis in its early 
development, mostly due to the lack of efficient methods for protein purification and 
apparent ease of use [136, 137]. However, this is cause for multiple issues, as whole cell 
biocatalysts not only contain the enzyme of choice (enoate reductase) but also various 
others, naturally expressed by the microorganism. The use of such systems where enoate 
reductase activity is present suffers mostly from side activities, leading to substrate 
and/or product depletion [12]. Competing alcohol dehydrogenase (ADH) for instance 
prevented isolation of the desired product (citronellal) in the reduction of citral with 
whole cells [52]. However, use of organic solvents could prevent further reduction of the 
product, and ADH activity was lowered by implementing the biphasic system with 
EDTA [51]. Besides, the presence of stereocomplementary enoate reductases within the 
same organism [53] or possibly racemase activity might lead to a loss of optical purity of 
the product, or more dramatically even to racemic mixtures. Therefore, most often 
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nowadays, the use of isolated enzymes and/or recombinant proteins in hosts lacking those 
side activities is favored (in a number of cases, it is still possible to obtain enantiopure 
products out of whole cell systems using wild-type organisms [51]). 
 
1.4.2. Cofactor regeneration systems 
Nicotinamide cofactor-dependent bioreduction of alkenes catalyzed by enoate 
reductases has started to emerge as a highly valuable technique for the production of 
optically active compounds; however, prohibitive costs of NAD(P)H render the process 
so far industrially not competitive with efficient metal-based catalytic hydrogenation. The 
key step to be studied before running large-scale synthesis using isolated enoate 
reductases is the recycling of the expensive redox cofactor. This can be performed via 
chemical, electrochemical, photochemical, microbial, or enzymatic reaction. The latter 
technique has been traditionally performed via “coupled-substrate” or “coupled-enzyme” 
approaches (Fig. 1.13, 1.14). 
 
 





Figure 1.14. Recycling of NAD(P)H via coupled-enzyme method (GDH = glucose 
dehydrogenase, FDH = formate dehydrogenase, G6PDH = glucose-6-phosphate 
dehydrogenase, PDH =  phosphite dehydrogenase). 
 
Cofactor recycling in biotransformations employing enoate reductases hitherto 
has been performed by either complex electro-microbial or -enzymatic cofactor recycling 
systems, based on toxic mediators, such as methylviologen Paraquat
TM
 [66, 70, 82, 138], 
or the traditional “coupled-enzyme” approach using FDH, GDH, G6PDH and more 
recently phosphite dehydrogenase [17, 25, 74, 87, 88, 139, 140]. 
Simon et al. used H2 as the electron donor in conjunction with anaerobic enoate 
reductase from Clostridia. They introduced a new recycling system, where cheap and 
stable methylviologen is oxidized by enoate reductases to its dicationic form upon 
reduction of the substrate (Fig. 1.15). The dication could be continuously reduced at an 
electrode and the system used for electro-enzymatic reduction (isolated enoate reductase), 
or in the form of bacterial cells (electro-microbial reduction). (2R)-2-Methyl-3-
phenylpropionate was prepared in 95% yield using the enoate reductase from Clostridium 
La 1. Care must be however taken that the unsaturated compounds do not react 





Figure 1.15. Reduction of C=C bond using methylviologen (MV) and an electrode as 
recycling system (EWG: electron withdrawing group, e
-
: electron from a cathode, ER: 
enoate reductase) [138]. 
 
As members of the OYE family tend to accept both cofactors equally well, no 
need for a specific nicotinamide enzyme is required [60, 81]. In some cases, the use of 
FDH was impacted by competitive carbonyl reduction, observed when an aldehyde 
moiety was present in the substrate. Prim-ADH activity in the commercial crude FDH 
preparation was inferred [87]. Furthermore, the need for additional divalent metal ions in 
the reaction mixture was recently reported to be necessary in the reduction of 
dicarboxylic acids to render the cofactor recycling feasible [85]. Despite those good 
results, limitations appear in the use of such systems. By coupling Yers-ER with glucose 
dehydrogenase (GDH) to recycle NADP(H), conversion of >99% within one hour was 
obtained for the reduction of 2-cyclohexenone. However, upon lowering the loadings of 
Yers-ER and GDH, rapid deactivation of either enzyme was observed due to the presence 
of enone substrate, rather than oxygen or elevated temperature. The stability limitations 
need to be overcome to envision large-scale use of enoate reductases in synthesis [17]. 
Enone toxicity was circumvented via the use of E. coli whole cells expressing the enoate 
reductase, along with a NADPH regeneration system [88]. 
Most recently, the combination of YqjM from Bacillus subtilis with visible light 
was used for the reductive regeneration of flavin, as flavins can be photochemically 
reduced by using simple sacrificial electron donors such as amines (e.g. EDTA). This 
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light-driven direct regeneration system was successfully employed for the reduction of 
ketoisophorone, yielding quantitatively (6R)-levodione with decent enantioselectivity 





1.4.3. Examples of industrial synthesis 
Enoate reductases selectively catalyze the reduction of C=C bonds in a strict 
trans-fashion, leading to the creation of up to two new stereogenic centers and thus 
constituting a valuable tool in asymmetric synthesis. Their exquisite chemo- and regio-
selectivity contributes to promote their use in industrial applications, as enantiopure 
compounds are becoming the standard, especially in the manufacturing of 
pharmaceuticals. 66% of the new drugs introduced in 2000 were indeed single 
enantiomers, compared with 21% in 1991 [142]. In 2001, single-enantiomer drugs 
represented 36% of the total drug market [143]. Currently, applications in non-food 
industries favor the use of recombinant enoate reductases and isolated enzymes over 





Figure 1.16. Examples of industrial syntheses implying reduction of C=C bonds (1. 2-
Methyl-5-phenyl-2,4-pentadienal to (S)-2-Methyl-5-phenyl-4-penten-1-ol; 2. 2-CAA: 2-
Chloroacrylic acid to 2-CPA: 2-Chloropropionic acid; 3. KIP: ketoisophorone to (6R)-
levodione; 4. Citral to (+)-citronellal) [41, 144-147]. 
 
The synthesis of -tocopherol (vitamin E) represents a challenge for synthetic 
chemists due to the presence of three stereocenters in the C29 framework of the molecule. 
One early method for the production of natural -tocopherol involved the asymmetric 
transformation of non-conventional substrates by baker‟s yeast starting from derivatives 
of 5-phenylpenta-2,4-dienal and clearly involving enoate reductase activity [144] (Fig. 
1.16-1). 
(R)-2-Chloropropionic acid (CPA) is used as a building block for the synthesis of 
phenoxypropionic acid herbicides (activity due to their (R)-isomers). The industrial 
synthesis of this class of herbicide involves the resolution of a racemic 2-CPA mixture, 
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via the enantioselective degradation of (R)-2-CPA by (R)-2-haloacid dehalogenase [148]. 
This kinetic resolution allows a maximum of 50% yield; therefore, asymmetric synthesis 
leading directly to the (R)-enantiomer would be valuable. A reductase from Burkholderia 
sp. WS has been shown to display activity in the asymmetric reduction of the carbon–
carbon double bond in 2-chloroacrylic acid (2-CAA), yielding (R)-2-CPA [41]. However, 
this enzyme was later identified as a 2-haloacrylate reductase [149]. Using recombinant 
E. coli cells coexpressing 2-haloacrylate reductase and a glucose dehydrogenase for 
NADPH regeneration, 37.4 g/l of enantiopure (S)-2-CPA were produced after 30 h, 
starting at a relatively high 2-CAA concentration of 385 mM  [150] (Fig 1.16-2). 
(4R,6R)-Actinol ((4R,6R)-4-hydroxy-2,2,6-trimethylcyclohexanone) is a useful 
intermediate for the synthesis of carotenoids, such as zeaxanthin, cryptoxanthin and 
xanthoxin [151-153]. Common synthetic strategies use ketoisophorone (KIP; 2,6,6-
trimethyl-2-cyclohexen-1,4-dione) as starting material, which upon asymmetric 
hydrogenation of the C=C bond forms (6R)-levodione (2,2,6-trimethylcyclohexane-1,4-
dione). Levodione is subsequently converted to enantiopure actinol via the asymmetric 
reduction of the carbonyl group (Fig 1.16-3).  
One early (partially) microbial method referred to the stereoselective fermentative 
hydrogenation of KIP using baker‟s yeast and subsequent reduction of (6R)-levodione in 
the presence of Al(CHMe2)3 or a Ni catalyst. More than two weeks were required to 
produce 60 mg/ml of (6R)-levodione (with the necessity of adding KIP continuously to 
prevent substrate inhibition) [151]. 
The first successful report of a full enzymatic system was made of a two-step 
enzymatic asymmetric reduction system in which OYE2 from Saccharomyces cerevisiae 
expressed in E. coli was used to stereospecifically reduce KIP to levodione, which was 
thereafter converted to the optically pure corresponding alcohol by levodione reductase 
from Corynebacterium aquaticum M-13, also expressed in E. coli. A glucose 
dehydrogenase was used in both steps for cofactor (NADH) recycling. Full conversion of 
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a 1% (wt/v) KIP aqueous solution was achieved within 2.5 h, yielding 9.5 mg of (4R,6R)-
actinol (94% ee) [145]. The microbial reduction of KIP to (6R)-levodione using growing 
cells of Saccharomyces cerevisiae was reported later, where in situ product crystallization 
(ISPC) was applied to prevent further degradation of levodione to unwanted by-products. 
A concentration of 100 g/l of enantiopure product was reached, corresponding to 85% 
yield (volumetric productivity of 0.92 g/l/h) [154]. The asymmetric reduction of KIP to 
(6R)-levodione has been also accomplished using E. coli cells co-expressing both OYE 
from Candida macedoniensis and a glucose dehydrogenase, rendering this synthesis of 
levodione highly advantageous. A 10% (wt/v) KIP solution was thus almost 
stoichiometrically converted to (6R)-levodione within 5.5 h (production efficiency of 18 
g/l/h) [155]. 
The production of flavor and fragrances represents a promising market for 
biocatalysis, as products labeled „natural‟ are more appreciated by consumers. As  flavor-
bearing chiral molecules usually occur as single enantiomers and different enantiomers 
often have different organoleptic properties, it is crucial to produce the right stereoisomer 
of the molecule [156].  Menthol is one of the most important flavoring chemicals due to 
its wide utilization (only (-)-menthol has the desired properties). Its estimated world 
production reached 19,000 metric tons in 2007 [152]. The Takasago process employs 
myrcene as starting material and a chiral rhodium phosphine catalyst (rhodium BINAP) 
for the asymmetric synthesis of (R)-(+)-citronellal, followed by cyclisation and 
hydrogenation reactions to yield (-)-menthol [146] (Fig. 1.16-4). Enoate reductases could 
potentially be introduced in the process as they reduce the -unsaturated bond of citral, 
an antimicrobial terpene, to produce citronellal [51, 52] (one example of a pure synthetic 
route from citral exists but mixtures of menthol enantiomers were obtained [147]). This 
reducing activity is well spread among microorganisms and both enantiomers can be 
obtained in pure form [51]. When using whole cells, a two liquid phase system was 
employed and suppressed the competing activities [25, 51] leading to both substrate and 
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product depletion observed [52]. This drawback was also circumvented by using isolated 
recombinant enzymes [60, 81]. The use of recombinant E. coli overexpressing 
Zymomonas mobilis NCR, coupled with a cofactor regeneration system (NADP
+
/GDH) 
in a binary solvent system (10% isopropanol (v/v)), led to a productivity of 9 mM/h for 
(S)-citronellal, starting from 20 mM citral, without any by-products being detected [25]. 
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INITIAL DEVELOPMENT & CHARACTERIZATION OF THREE 
ENOATE REDUCTASES IN THE GROUP 
 Enoate reductases (ERs) selectively reduce carbon-carbon double bonds in α,β-
unsaturated carbonyl compounds and thus can be employed to prepare enantiomerically 
pure aldehydes, ketones, and esters. Most known ERs, most notably Old Yellow Enzyme 
(OYE), are biochemically very well characterized. Some ERs have only been used in 
whole-cell systems, with endogenous ketoreductases often interfering with the ER 
activity. Not many ERs are biocatalytically characterized as to specificity and stability. 
Here, the group cloned the genes and expressed three non-related ERs, two of them 
novel, in E. coli: XenA from Pseudomonas putida, KYE1 from Kluyveromyces lactis, 
and YersER from Yersinia bercovieri. All three proteins showed broad ER specificity and 
broad temperature and pH optima but different specificity patterns. All three proteins 
prefer NADPH as cofactor over NADH and are stable up to 40 
o
C. By coupling YersER 
with glucose dehydrogenase (GDH) to recycle NADP(H), conversion of >99% within 
one hour was obtained for the reduction of 2-cyclohexenone. Upon lowering the loadings 
of YersER and GDH, we discovered rapid deactivation of either enzyme, especially of 
the thermostable GDH. We found that the presence of enone substrate, rather than 
oxygen or elevated temperature, is responsible for deactivation. In summary, we 
successfully demonstrate the wide specificity of enoate reductases for a range of α,β-
unsaturated carbonyl compounds as well as coupling to glucose dehydrogenase for 
recycling of NAD(P)(H); however, the stability limitations we found need to be 





2.1 Enoate Reductase Characterization & Purification 
 Three enoate reductase candidates were cloned and expressed in E. coli: 
xenobiotic reductase A (XenA) from Pseudomonas putida, KYE1 from Kluyveromyces 
lactis, and YersER from Yersinia bercovieri. Amino acid sequence identities and 
similarities between the three candidates with other known ERs were tabulated in Table 
2.1. The three gene products were cloned into pET27 and pET28 for expression of ERs 
with and without N-terminal polyhistidine tag. Only XenA showed activity decrease in 
the presence of N-terminal histag. Both KYE1 and YersER showed same activity level 
with 2-cyclohexenone and were purified with Ni
2+
-NTA bead protocol. XenA was 
purified according to published protocol with the combination of DEAE-column and Q-
sepharose column.[1] Purification procedures of all three candidates were monitored with 
SDS-PAGE (Fig 2.1) to ensure the final purity before proceeding to substrate 
characterizations.  
  
Figure 2.1. YersER purification SDS-PAGE. Lane 1: cell lysate lane 2: binding step flow 




 The specific activity of the three ERs was calculated based on NADPH molar 




 at 340 nm reading. The enzyme assay condition 
was standardized for substrate characterization: 200 mM sodium phosphate buffer pH 
7.5, 10 mM of substrate, 0.2 mM NADPH, and 25 
o
C. The result showed all three 
candidates possessed broad substrate spectrum and successfully reduced almost all tested 
substrates with satisfactory specific activity (Table 2.2). The stability of the ERs was 
tested towards thermal deactivation at three different temperatures of 30, 37 and 45 
o
C, 
where YersER was proven to be the most thermo stable candidate with half-life of 
>13124 min at 45
 o
C. The collected data showed YersER possessed a broad substrate 
spectrum with overall high specific activity profiles even at high temperatures, so we 
decided to optimize its operating conditions by measuring activity-temperature profile 
and pH-activity profile. The result showed that highest activity of YersER was observed 
at 50 
o
C and pH 7. [2] 
 
Table 2.1. Amino acid sequence identities and similarities between XenA, KYE1, and 









Table 2.2. The specific activity on different α,β-unsaturated carbonyl compounds. nd = 
not determined  
Substrate Structure 
Specific Activity [U/mg] 




1.54 2.74 4.22 
trans,trans-2,4-hexadienal  1.51 3.18 2.19 
citral 
 
0.67 1.75 1.97 
cinnamaldehyde 
 
2.30 1.56 2.91 
(R)-carvone 
 
0.73 Nd 2.54 
3-methyl-2-butenal 
 
0.45 Nd 0.39 
maleic anhydride 
 
0.86 1.91 5.20 
ketoisophorone 
 
1.33 1.84 10.11 
maleimide 
 
2.04 25.8 18.9 
N-ethylmaleimide 
 
2.46 14.9 15.8 
but-3-en-2-one 
 
2.14 22.7 14.8 
ethyl-3-(2-furyl)-propanoate 
 








2.2 Cofactor Specificity of YersER, KYE1, and XenA 
 After testing substrate specificity, the cofactor preference of the three ERs was 
checked with four different enone substrates (Table 2.3). NADPH was always the 
preferred cofactor, and the enzymes showed very little or no activity with NADH. 
Interestingly, the choice of enone substrate seems to influence the NADPH/NADH 
specificity ratio. While NADPH did not react at all in the presence of 2-cyclohexen-1-one 
and rarely in presence of maleimide, all three ERs showed activity with NADH in 
presence of methyl vinyl ketone and ethyl-3-(2-furyl)propanoate. This phenomenon is all 
the more interesting, as ER is known to react according to a ping-pong mechanism, i.e., 
the reductive (substrate) and oxidative (FMN by NADPH) half-reactions occur 
independently, thus, the different enone substrates should not influence cofactor 
specificity. 
Table 2.3. Cofactor preference for YersER, KYE1, and XenA 
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2.3 Enzyme Stability at Different Temperatures 
 The lack of stability of enzymes against heat and organic solvents can hamper 
their economical application. We investigated the thermal tolerance of all three ERs by 
taking samples after various incubation times at three temperatures (30, 37, and 45 
o
C) 
and measuring residual activity at 25 
o
C. We always found deactivation to fit a first-order 
rate law. Although none of the three proteins is particularly thermostable, YersER at 37 
o
C was 25-fold and 7-fold more stable than XenA and KYE1, respectively (Table 2.4). 
YersER at 45 
o
C in degassed solution deactivates with a half-life of 129 min, compared 
with 117 min in air-saturated solution, which demonstrates that oxygen has no influence 
on stability. The half-life of XenA and KYE1 at that temperature was less than 5 min. 
Since sufficient stability is an important factor for biocatalysis, we chose the YersER for 
further characterization.  
 
Table 2.4. Half-lives of enoate reductase and glucose dehydrogenase: (a) In the presence 
of 25 g/L of 2-cyclohexen-1-one. (b) In the presence of 25 g/L of 2-cyclohexanone. (c) 







2.4 Coupling of the ERs with the Cofactor Recycling System 
 The coupling of YersER with GDH was performed in the batch mode (Fig 2.2). 
Enoate reductase from Yersinia bercovieri and GDH-103 (a glucose dehydrogenase from 
Biocatalytics, Pasadena, CA) were added in different ratios to a 200 mM phosphate 
buffer of pH 7.5, 299 mM glucose and 1.2 mM of NADP+. The reaction was performed 
in the batch mode at 30 
o
C and substrate cyclohexen-1-one was added to a final 
concentration of 260 mM. The work was carried out at 125 mg scale (5 mL total volume), 
the temperature was maintained at 30 
o
C using a water bath, pH was adjusted manually 
using 2 M NaOH and agitation was achieved using a magnetic stirrer at 200 rpm. The 
conversion was determined via gas chromatography (GC) by measuring the substrate and 
product content of a reaction sample extracted with ethyl acetate using an Agilent GC-
FID (model 6890) with a DB17 column (Agilent, Palo Alto, CA). 
 
Figure 2.2. Enzyme-coupled cofactor regeneration system with enoate reductase from 
Yersinia bercovieri and glucose dehydrogenase (GDH-103). 
 
 All reactions were run at 30 
o
C in 200 mM phosphate buffer (pH 7.5) containing 
25 g/L (260 mM) of the substrate 2-cyclohexen-1-one, 53.8 g/L (299 mM, 15% molar 
excess) of glucose, 1 g/L (1.2 mM) of cofactor NADP
+
 and both enzymes at varying 
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ratios of kU/L. Four reactions were run at these conditions at 8:16, 8:8, 4:8, and 2:4 kU/L 
of YersER to GDH-103, respectively (Fig 2.3).  
 
Figure 2.3. Enzymatic oxidation of 25 g/L of 2-cyclohexen-1-one to 2-cyclohexanone at 
30 
o
C in 200 mM phosphate pH 7.5. 
  
 It is evident that enzyme loading had a significant effect on reaction rate. At 8:16 
kU/L of YersER to GDH-103, the reaction reached >99% conversion within an hour (217 
turnovers), while at a loading of 8:8 kU/L the reaction required 6 h for the same degree of 
conversion (>99%) (Fig 2.3). This difference in reaction rate might be explained by the 
increased supply of reduced cofactor achieved at a higher loading of GDH-103. At more 
diluted levels of YersER and GDH-103, 4:8 kU/L and 2:4 kU/L, >99% and >16% 
conversion were measured after 29 h, respectively. Such a dramatic difference in reaction 
rate between the 8:16 kU/L and the 4:8 kU/L enzyme loadings for YersER and GDH-103 
suggests significant enzyme deactivation at the operating conditions.  
 To test this hypothesis, the residual activities of YersER and GDH-103 were 
monitored separately in batch experiments in the presence of reactant or product at the 
operating conditions (30 
o
C, 200 mM phosphate pH 7.5 and 25 g/L of 2-cyclohexen-1-
one or 2-cyclohexanone) in the absence of cofactor. The residual activity was measured 
by monitoring NADP(H) depletion (YersER) or formation (GDH-103). Assuming first-
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order deactivation (corroborated above for ER and independently verified for GDH from 
various organisms), half-lives were estimated for YersER to be 78 min and 48 h in the 
presence of reactant (2-cyclohexen-1-one) and product (2-cyclohexanone), respectively. 
For GDH-103, the half-lives were estimated to be 1.6 min and 9.4 h in the presence of 
reactant and product, respectively. The addition of 260 mM 2-cyclohexen-1-one leads to 
a more than 30-fold decrease of the half-life at 30 
o
C from >2160 min to 78 min for 
YersER. A high degree of precipitation was observed in both enzyme samples which 
contained 260 mM 2-cyclohexen-1-one. 
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NITROREDUCTASE FROM SALMONELLA TYPHIMURIUM:  
CHARACTERIZATION AND CATALYTIC ACTIVITY  
 
 The biocatalytic activity of nitroreductase from Salmonella typhimurium (NRSal) 
was investigated for the reduction of α,β-unsaturated carbonyl compounds, nitroalkenes, 
and nitroaromatics. The synthesized gene was subcloned into a pET28 overexpression 
system in E.coli BL21 strain, and the corresponding expressed protein was purified to 
homogeneity with 15% protein mass yield and 41% of total activity recovery. NRSal 
showed broad substrate acceptance for various nitro compounds such as 1-
nitrocyclohexene and aliphatic nitroalkenes (alkene reductase activity), as well as 
nitrobenzene (nitroreductase activity), with substrate conversion efficiency of > 95%. 
However, the reduction of enones was generally low, proceeding albeit with high 
stereoselectivity. The efficient biocatalytic reduction of substituted nitroalkenes provides 
a route for the preparation of the corresponding nitroalkanes. NRSal also demonstrated 
the first single isolated enzyme-catalyzed reduction of nitrobenzene to aniline through the 
formation of nitrosobenzene and phenylhydroxylamine as intermediates. However, 
chemical condensation of the two intermediates to produce azoxybenzene currently limits 




Fig 3.1. Nitroreductase NRSal from Salmonella typhimurium displays both nitroreductase 
and enoate reductase activity in the asymmetric reduction of C=C bonds and aromatic 
nitro compound.  It also demonstrated the first single isolated enzyme-catalyzed 
reduction of nitrobenzene to aniline. 
 
3.1 Introduction 
 Flavoenzymes are biocatalysts that catalyze a wide range of biochemical reactions 
ranging from dehydrogenation, one- and two-electron transfer redox reactions, oxygen 
activation during oxidation and hydroxylation reactions, to light emission in 
bioluminescent bacteria.[1, 2]
 
As part of flavoenzymes, the recently growing “Old 
Yellow Enzyme” (OYE) family was reported to catalyze the reduction of various 
substrates such as α,β-unsaturated aldehydes, ketones, imides, esters, nitriles, and 
carboxylic acids.[3-6] The asymmetric bioreduction of C=C bonds employing OYE 
family proteins can create up to two chiral centers and therefore constitutes an interesting 
route towards enantiomerically pure compounds. The C=C bond reduction catalyzed by 
enoate reductases proceeds via a ping-pong mechanism, where the flavin is first reduced 
at the expense of a nicotinamide cofactor in the reductive half-reaction, followed by the 
asymmetric reduction of the substrates through trans-hydrogenation (oxidative half-
reaction).[7-9] The OYE family also features nitroreductase activity through 
biodegradation of explosive compounds such as PETN, TNT, and nitroglycerin. Several 
members of the OYE family such as XenA and XenB from Pseudomonas sp.,[10, 11] 
PETN reductase from Enterobacter cloacae,[12, 13] OYEs from Saccharomyces sp.,[6, 
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14] YqjM from Bacillus subtilis,[15, 16] and OPRs from Arabidopsis thaliana[17, 18] 




 In our previous work, we have characterized three un-related enoate reductases: 
XenA from Pseudomonas putida, KYE1 from Kluyveromyces lactis, and YersER from 
Yersinia bercovieri. We have shown that these three enoate reductases feature broad 
substrate specificity but different substrate preferences on a set of various α,β-unsaturated 
carbonyl compounds.[3] Since enoate reductases often possess nitroreductase activity, we 
initiated a new search for a candidate that possesses broad substrate specificity for nitro 
compounds, however, applying a different strategy: the investigation of nitroreductases 
for their enoate reductase activity, with specific emphasis on the biocatalytic reduction of  
nitroalkenes to provide an efficient route for the synthesis of chiral substituted 
nitroalkanes. This strategy was based on the observation that some nitroreductases had 
shown reductase activity on quinones.[19-22]  
3.1.1 Reduction of nitro compounds 
 Nitroalkanes are potential intermediates in the synthesis of amines, aldehydes, 
carboxylic acids or denitrated compounds.[23, 24] The traditional organic synthesis of 
enantiomerically pure nitroalkanes occurs through asymmetric conjugate addition to 
nitroalkenes,[25-27] reduction of nitroalkenes with transition metal catalyst,[28] 
hydrogenation with Jacobsen-type organocatalyst,[29] or addition of α,β-unsaturated 
bonds onto nitroalkanes.[30] Due to various restrictions on these organic synthesis 
processes (such as growing environmental restrictions on the type of catalyst used, 
narrow substrate acceptance), an efficient biocatalytic route for chiral nitroalkanes is 
highly desirable. Recently, several published works have demonstrated stereoselective 
reduction of nitroalkenes using: OPR1 and OPR3 from Lycopersicon esculentum,[15, 16] 
OYE from Saccharomyces carlsbergensis and OYE2-3 from Saccharomyces 
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cerevisiae,[6, 14] NCR from Zymomonas mobilis,[6, 14] YqjM from Bacillus subtilis,[15, 
16] PETN reductase from Enterobacter cloacae,[12, 13] and crude enzyme preparation 
from Clostridium sporogenes.[31] These enzymatic processes are a valuable addition to 
the established synthetic toolbox and inspire the search for new candidates.    
 In this context, we came across a homolog of nitroreductase from Enterobacter 
cloacae: nitroreductase from Salmonella typhimurium (NRSal). NRSal was first 
discovered in 1989 from Salmonella typhimurium strain TA1538NR,[32]
 
and represents a 
new class of flavin-dependent nitroreductase enzymes.[21, 33-35] The nucleotide 
sequence of this oxygen-insensitive FMN-containing NRSal encodes for 217 amino 
acids, with a calculated molecular weight of 23,955 Da. This enzyme has been shown to 
reduce some nitroaromatic compounds, such as p-nitrophenol or p-nitrobenzoic acid.[36] 
Since then however, there has been no published work about any further characterization 
of NRSal, and especially its catalytic activity, which renders it an interesting candidate 
for us to explore. In this paper, we examine the ability of NRSal to catalyze the reduction 
of α,β-unsaturated carbonyl compounds, nitroalkenes, and nitroaromatics.   
 
3.2 Results & Discussion 
3.2.1 Cloning, overexpression, and purification  
 The gene coding for NRSal was purchased from BioBasic Inc (Ontario, Canada) 
according to the published sequence (UnitProtKB accession # P15888).[32, 37]  
Sequence analysis revealed that NRSal from Salmonella typhimurium shares high amino 
acid identity and similarity with nitroreductase from Enterobacter cloacae with 89% 
identity and 93% similarity (Figure 3.2). The gene product was cloned into vector 
pET28a(+) (Novagen, San Diego, CA) at the following restriction sites: NcoI and HindIII 
with stop codon for expression of wild type NRSal, NcoI and HindII for expression of 
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NRSal with C-terminal polyhistidine tag, and NdeI and HindIII with stop codon for 
expression of NRSal with N-terminal polyhistidine tag. The addition of the polyhistidine 
tag was for ease of enzyme purification.  
 
Figure 3.2. Amino acid alignment of nitroreductase NRSal from Salmonella typhimurium 
(P15888, NR_Sal) and nitroreductase from Enterobacter cloacae (Q01234, NR_ENT) 
using EMBOSS Pairwise Alignment Needle Algorithm (http://www.ebi.ac.uk). 
 
 The purification of wild-type NRSal was optimized compared to previously 
published method.[36] The original six steps of NRSal purification were reduced to two 
steps, with first ammonium sulfate precipitation to remove the majority of non-
proteinaceous biological material, followed by anion exchange column chromatography 
with DEAE-Sepharose column to isolate pure NRSal with 15% protein mass recovery 
from the cell lysate sample, and with total activity recovery of 41%. The purification of 
wild-type NRSal was monitored with the standard activity assay on nitrofurazone[36] 
(Table 3.1) followed by SDS-PAGE analysis (Figure 3.3). The final elution showed a 
single band upon SDS-PAGE analysis. The NRSal with N- or C-terminal polyhistidine 
tag was purified according to the standard Ni
2+
-NTA bead protocol from Qiagen 
(Valencia, CA). However, the activity of NRSal with polyhistidine tag was found to be 
much lower compared to the wild type. Activity check was performed by monitoring the 
reduction of nitrofurazone (known substrate for NRSal[36]) and cyclohexenone (common 
substrate for enoate reductases). NRSal with N- or C-terminal polyhistidine tag showed 
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specific activity of 4.40 U/mg and 3.27 U/mg respectively for nitrofurazone reduction, 
which was much lower compared to wild type specific activity of 14.2 U/mg. An 
analogous pattern was observed for the reduction of cyclohexenone, where wild type 
NRSal showed significantly higher specific activity (0.39 U/mg) compared to NRSal with 
N-terminal (0.16 U/mg) and C-terminal (0.17 U/mg) polyhistidine tag. Since the presence 
of the polyhistidine tag considerably decreased enzymatic activity of NRSal, further 
characterization was continued only with wild-type, untagged-NRSal.  
 

















Lysate 53.3 285 5.34 100 
(NH4)2SO4 22.4 136 5.02 48 
Dialysis 22.0 149 6.78 52 
DEAE 8.20 116 14.2 41 
[a] 
Dry cell weight 1.1 g/L. 
[b]
 Nitrofurazone activity assay: 50 mM TrisHCl buffer pH 7.2, 0.05 mM Nitrofurazone, 
0.1 μM NRSal, GDH recycling system: (8 μM NADPH, 2 mM Glucose, 10 U GDH). The 
activity was calculated by monitoring the decrease of nitrofurazone wavelength at 375 










Figure 3.3. SDS-PAGE analysis for purification of wild type NRSal: Lane 1 protein 
ladder, lane 2 cell lysate sample, lane 3 70% (NH4)2SO4 precipitation, lane 4 DEAE-
Sepharose column. 
 
3.2.2 Enzymatic activity and stability study 
We first investigated the effect of temperature and pH on NRSal by monitoring 
the change of enzymatic activity over the range of 10 – 60 °C (Figure 3.4), and pH range 
of 4 – 9 (Figure 3.5). The activity-temperature profile showed maximum specific activity 
of 13.6 U/mg for reduction of nitrofurazone at 45 °C and pH 7.5, which was 3.2-fold 
higher than the activity at room temperature (20 °C). Arrhenius plots yield an activation 
energy Ea of 42.7 kJ/mol for the temperature range of 10 – 45 °C (r
2
 = 0.963), and a 
deactivation energy Ed of -31.5 kJ/mol for the temperature range of 45 – 60 °C (r
2 
= 
0.965). The activity-pH profile showed an optimum pH at 7.2 with highest specific 
activity of 8.10 U/mg for reduction of nitrofurazone at 20 °C in 50 mM TrisHCl buffer. 
We also found that NRSal had lower activity (but similar activity–pH pattern with a 
maximum activity at pH 7.2) in 50 mM phosphate buffer compared to 50 mM TrisHCl 
buffer. The activity of NRSal is therefore buffer dependent and TrisHCl is the optimum 
buffer for reactions run between pH 6 – 7.5. Additionally, NRSal considerably lost its 
activity beyond pH 8.  
Since thermal stability of enzymes is a key consideration for application in larger 
scale processes, we investigated the kinetic stability of NRSal by measuring its half-life 
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at three different temperature points of 37, 45, and 50 °C (Table 3.2). The deactivation of 
NRSal at all temperatures followed first order deactivation kinetic (data not shown). 
Also, NRSal seemed reasonably stable with shortest half-life of 2.3 hours measured at 50 
°C, and half-life decreased exponentially with increasing temperatures.   
 
 
Figure 3.4. Activity – temperature profile of NRSal. Activity was measured with standard 




Figure 3.5. Activity – pH profile of NRSal in three different buffers: 50 mM TrisHCl (x), 
20 mM citrate buffer (▲), and 50 mM phosphate buffer (■). Activity was measured with 














37 365 hours 0.0019 hour
-1
 
45 17.9 hours 0.0388 hour
-1
 




kd,obs is the observed deactivation rate constant 
3.2.3 Substrate spectrum characterization 
 With finding of a broad enoate reductase activity in a nitroreductase as one of our 
goals, we investigated the catalytic activity of purified NRSal with several common α,β-
unsaturated carbonyl substrates for enoate reductases (Table 3.3. Entries #1–4). We first 
tested NRSal activity on cyclohex-2-enone (1) and related substrate 3-methyl-2-
cyclohexenone (2).[39-41] The nitroreductase enzyme displayed enoate reductase activity 
on both substrates. Both compounds 1 and 2 were reduced, albeit with maximum 
substrate conversion of only 12% and 5.2% respectively. NRSal showed strong 
stereospecificity in the reduction of 2 and yielded (R)-3-methyl-2-cyclohexanone with 
84% e.e.. Substrates ketoisophorone (3) and citral (4) were also tested due to their large-
scale industry application to produce the corresponding levodione and citronellal, 
respectively.[42-45] NRSal showed modest maximum conversion of 12% with 3 to 
produce (R)-levodione with 87% e.e, and did not show any biocatalytic reduction of 
aldehyde 4. This remarkable stereoselectivity for a nitroreductase in reducing C=C bonds 
may point at a mechanism similar to that of OYEs, as OYEs proceed via a ping pong Bi 
Bi mechanism, as do nitroreductases in the reduction of the nitro group.[7-9, 20, 21]    
 Despite the low conversions with α,β-unsaturated carbonyl substrates, we 
hypothesized that NRSal, as a nitroreductase, would display stronger alkene reductase 
activity in the presence of a nitro group. Indeed, NRSal showed broader substrate 
acceptance for nitro related compounds (Table 3.3. Entries #5-8). First, we observed the 
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reduction of C=C bond on nitro compounds 5 to 7. Maximum conversion of 1-
nitrocyclohexene (5) was 97% to produce the reduced product 1-nitrocyclohexane. 
Aliphatic nitroalkenes (6-7) were also shown to be favored substrates of NRSal with 
overall conversion efficiency of > 95%. Both compounds 6 and 7 were reduced to the 
corresponding alkanes, with compound 7 being reduced to the racemic product; either the 
enzyme was not stereoselective for that compound, or alternatively the potential 
enantiomeric product could have racemized due to the acidity of the proton on Cα. 
Finally, we observed a more typical behavior for a nitroreductase in the reduction of 
aromatic nitro compound such as nitrobenzene (8), which was reduced with conversion 
of > 99% to produce nitrosobenzene, phenylhydroxylamine, but also aniline and the 
chemical condensation product azoxybenzene. To our knowledge, this is the first report 
of a single enzyme-catalyzed reduction of nitrobenzene to aniline (reaction detailed in the 
next section).  
  Overall, NRSal accepts both cofactors NADPH / NADH equally well, with higher 
substrate acceptance for compounds containing the electron withdrawing nitro group. 
Importantly, the diverse catalytic activity of NRSal was reflected in the broad substrate 











Table 3.3. Biocatalytic conversion of various α,β-unsaturated carbonyl compounds, 
nitroalkenes, and nitroaromatic substrates with NRSal (* represents a chiral center). 
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Aniline / Nitrosobenzene / Phenyl-hydroxylamine / 
Azoxybenzene 
Both >99% 





3.2.4 Enzymatic reduction of nitrobenzene to aniline  
 The enzymatic reduction of nitroaromatic compounds can follow two pathways: 
the reduction of the nitro group or the reduction of the aromatic ring. The nitro group 
reduction is either a one-electron or two-electron reduction mechanism.[46] Both 
mechanisms involve the reduction of the nitro group to the amine through highly reactive 
nitroso and hydroxylamino intermediates. The aromatic ring in nitroaromatic compounds 
can also be reduced, resulting into the corresponding Meisenheimer complex, followed 
by subsequent release of nitrite.[47, 48] The formation of the Meisenheimer complex has 
been observed for several members of the OYE family such as PETN reductase from 
Enterobacter cloacae,[49] XenB from Pseudomonas fluorescens,[50] and NemA from 
Escherichia coli,[51] which also display nitroreductase activity on the nitro group. 
 Published work on the reduction of nitrobenzene to aniline was mainly 
accomplished with metal support catalysts (e.g Ru/SBA, Ni, Pt/C catalysts) or whole-cell 
biocatalysts (e.g Rhodotorula mucilaginosa, Arracacia xanthorrhiza, Candida 
guilliermondii, Saccharomyces cerevisiae).[52-57] The single enzyme-catalyzed 
reduction of nitrobenzene (e.g with nitrobenzene nitroreductase from Pseudomonas 
pseudoalcaligenes JS45) was reported to produce phenylhydroxylamine, a highly reactive 
intermediate.[58, 59] To the best of our knowledge, the discovery of NRSal reduction of 
nitrobenzene represents the first single isolated enzyme-catalyzed reduction of 
nitrobenzene to aniline. The mechanism for NRSal nitrobenzene reduction was shown to 
follow the two-electron reduction pathway of the nitro-group: nitrobenzene was reduced 
to form nitrosobenzene first and phenylhydroxylamine next, followed by subsequent 
reduction of phenylhydroxylamine to aniline. At the same time, chemical condensation 
between the nitrosobenzene and phenylhydroxylamine resulted in the production of 
azoxybenzene (Figure 3.6).[60, 61] Control experiments were performed to demonstrate 
the condensation reaction by mixing of these standards under similar reaction conditions 
but without enzyme present. Real-time analysis was performed to quantify the reduction 
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of 1 mM nitrobenzene over time course of 160 min: nitrobenzene was completely 
converted within 40 minutes (with conversion of > 99%), along with the formation of 
0.26 mM nitrosobenzene, 0.09 mM phenylhydroxylamine, 0.06 mM aniline, and 0.35 
mM azoxybenzene (Figure 3.7). Nitrobenzene and phenyl-hydroxylamine were found to 
be chemically unstable and were completely degraded after 6 hours, with no further 
increase of aniline as final product. In an effort to boost the percentage formation of 
aniline in the overall reaction, one possible method was to limit the condensation between 
nitrosobenzene and phenylhydroxylamine. Experiments were performed to remove 
molecular oxygen from the reaction system as initial hypothesis that O2 was essential in 
the condensation reaction. However, azoxybenzene formation was still detected at similar 




Figure 3.6. Proposed nitrobenzene reduction pathway to aniline and azoxybenzene by 
NRSal. 
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Figure 3.7. Conversion-time plot for the reduction of nitrobenzene by NRSal in the 
presence of NADH. 
 
3.3 Conclusion 
 In summary, nitroreductase NRSal from Salmonella typhimurium is a versatile 
biocatalyst that displays both nitroreductase and enoate reductase activity. The enzyme 
showed strong preference in the reduction of C=C bonds for nitro-containing substrates, 
with less satisfactory biocatalytic activity towards the reduction of C=C bonds in enones, 
still with a high stereoselectivity. It is interesting that a true nitroreductase presents strong 
enoate reductase activity with substrate stereopreference, is an FMN-bound enzyme and 
is still not associated with OYE family. The feasibility of biocatalytic reduction of 
nitroalkenes to nitroalkanes provides an addition as part of the synthetic toolbox to obtain 
various intermediates of interest. This is also the first isolated single enzyme-catalyzed 
reduction of nitrobenzene to aniline, which provides a possible perspective for a green 
production process of anilines other than traditional synthesis through chemical 
hydrogenation and metal-supported catalyst.
[46]
 Although overall aniline formation is still 
limited due to condensation reaction in the system, we are currently investigating for 
optimized reaction conditions and larger scale reaction system.  
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3.4 Meterials & Methods 
3.4.1 NRSal orimer sequences, cloning, and expression  
 The DNA sequence of NRSal from Salmonella typhimurium was synthesized by 
BioBasic Inc (Ontario, Canada) according to UnitProtKB accession # P15888. The 
corresponding specific 5’- and 3’-primers were synthesized at Eurofins-mwg|operon 
Biosciences (Huntville, AL). The primers contain a gene-encoding segment (italic), a 
restriction site (underlined), and an overhang. The 5’-primers of wild type and C-terminal 
polyhistidine tagged introduced a NcoI restriction site (5’-CAT GCC ATG GCA ATG 
GAT ATT GTT TCC GTA GCT CTG C-3’), and N-terminal tagged introduced a NdeI 
restriction site (5’-GGG AAT TCC ATA TGA TGG ATA TTG TTT CCG TAG CTC TGC-
3’) into the PCR fragment. The 3’-primer introduced a HindIII restriction site in to the 
PCR fragment (with stop codon: 5’-CCC AAG CTT TTA CAC TTC AGT CAG GGT 
GGT TTC CA-3’, and without stop codon: 5’- CCC AAG CTT CAC TTC AGT CAG 
GGT GGT TTC CA-3’).  
 DNA amplification was performed with standard PCR protocol with Pfu 
polymerase from New England Biolabs (Marlborough, MA) and PCR buffer from 
Stratagene (La Jolla, CA). DNA was amplified for 30 cycles in an Eppendorf Gradient 
Thermocycler (Eppendorf, Hamburg, Germany) followed by gel purification with 
standard Qiagen gel kit (Qiagen, Valencia, CA). PCR assay: 100 ng of DNA, 200 µM of 
each dNTP, 10 µM of each primers, 1 U of Pfu polymerase, and 5 µL of Pfu buffer in a 
 68 
final volume of 50 µL. Each DNA amplification cycle: 1 min denaturation at 95 °C, 1 
min annealing step at 50, 55, and 60 °C, 3.5 min extension step at 68 °C. The final PCR 
products were digested with restriction enzymes and ligated into pET28a (+) (Novagen, 
San Diego) and transformed into competent E. coli XL1-Blue cells. The NRSal genes 
were sent for DNA sequencing at Eurofins-mwg|operon Biosciences (Huntville, AL).  
 The NRSal genes were transformed into E. coli BL21 for protein expression. 
Starter culture consisted of 5 ml LBKan inoculated from frozen stock and grown overnight 
at 37 °C. The starter culture were used for inoculation of 300 ml culture (0.1% v/v), 
which was gently aerated until OD600 reached 0.5 for addition of 0.1 mM of IPTG and 
left overnight for protein expression. Harvested cell pellets were kept for -80 °C for 
protein purification.  
3.4.2 Purification of NRSal 
 The cell pellets of wild type NRSal were re-suspended in 50 mM TrisHCl buffer 
pH 7.5 (buffer A) and disrupted by sonication. The supernatant was separated after 
centrifugation, where NRSal was precipitated between 40-70% of saturated ammonium 
sulfate. The precipitate was dissolved again in buffer A and dialyzed over 6 hours. The 
dialyzed sample was applied to DEAE-Sepharose
TM
 FF (GE Healthcare, Sweden) column 
and washed with 25 mM step increment of NaCl in buffer A. Purified NRSal was 
collected at elution of 150 mM NaCl with 0.1 mM of free FMN added to account for the 
loss of FMN during the purification (only 20% FMN occupancy measured before 
addition of free FMN). Although experiments were performed to measure for the FMN 
occupancy at the end of purification, free FMN in the sample seemed to saturate the 
spectrophotometer measurement even with multiple wash cycles. The NRSal with N- or 
C-terminal polyhistidine tag were purified with Ni
2+
-NTA beads according to the 
standard protocols of Qiagen (Valencia, CA). The protein concentration was determined 
by the Bradford method with Coomassie Plus Protein assay reagent and BSA assay 
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(Pierce Chemical) as the calibration curve. SDS-PAGE analysis was performed with 50 
µg protein sample elution into each well. The protein samples were mixed with 2X 
sample buffer (125mM TrisHCl, pH 6.8, 4% SDS, 50% glycerol. 0.02% bromophenol 
blue, and 10% 2-mercaptoethanol). The mixed samples were incubated at 100 °C for 5 
min and loaded onto 12% PAGE
TM
 Gold precast gel and run in BioRad Mini Protean 
chamber (BioRad, Hercules CA) at 150 V for 45 min with Tris-HEPES-SDS running 
buffer (12.1 g/L Tris, 23.8 g/L HEPES, 1 g/L SDS). Biorad Precision Plus protein ladder 
was used as standards in the gel analysis. GelCode
®
 Blue Stain Reagent (Pierce, 
Rockford IL) was used for final gel staining.     
3.4.3 Enzyme assay 
 NRSal kinetic measurement were performed by monitoring the oxidation of 




. Reaction assays were analyzed with 
Shimadzu GC-2010 using RT-BDEXcsf chiral column (30 m 0.32 mm 0.25 µm, Restek) 
for entry # 1 – 4; Cyclosil-B chiral column (30 m 0.32 mm 0.25 µm, J&W Scientific) for 
entry # 6 – 8; and SHRX5 column (15m 0.25 mm 0.25 µm Shimadzu) for entry # 5. All 
substrates and products were purchased commercially from Sigma Aldrich or VWR with 
highest purity available except products of entry #6 - 8, and phenyl-hydroxylamine. Prof. 
Jim Spain Research Group (Georgia Institute of Technology) kindly provided synthesized 
phenylhydroxylamine.[62] Products of 6 – 7 were synthesized according to previous 
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CHARACTERIZATION OF XENOBIOTIC REDUCTASE A:  
STUDY OF ACTIVE SITE RESIDUES,  
SUBSTRATE SPECTRUM, AND STABILITY 
  
 Xenobiotic reductase A (XenA) has broad catalytic activity and reduces various 
α,β-unsaturated and nitro compounds with moderate to excellent stereoselectivity. Single 
mutants C25G and C25V are able to reduce nitrobenzene, a non-active substrate for the 




Figure 4.1. Asymmetric trans-bioreduction of C=C bonds coupling XenA with cofactor 
recycling system through half-oxidative and half-reductive reaction (EWG = electron 







 The Old Yellow Enzyme (OYE) family is a class of flavin-dependent enzymes 
that catalyze the stereoselective reduction of activated C=C bonds at the expense of 
nicotinamide cofactors.  This asymmetric bioreduction creates up to two new stereogenic 
centers and thus has gained increasing interest as a new tool in chiral intermediates 
synthesis.[1-3]
 
Members of the OYE family were reported to catalyze the bioreduction of 
a variety of different substrates such as α,β-unsaturated aldehydes, ketones, imides, nitro 
groups, nitriles, carboxylic acids, nitro esters, and nitro aromatics.[4-6]    
4.1.1 Background on xenobiotic reductase A 
 The catalytic activity of xenobiotic reductase A (XenA) from Pseudomonas 
putida was first reported for the reduction of nitroglycerin (reductive denitration), TNT 
(reduction of nitro group) and 2-cyclohexen-1-one (reduction of olefinic bond),[7] and 
later for nitroreductase activity for Research Department Explosive (RDX) and a series of 
nitroaromatic and nitramine explosive compounds.[8] This FMN containing enzyme was 
also shown to display broad enoate reductase activity over various α,β-unsaturated 
carbonyl compounds such as citral, ketoisophorone, maleimide,[9] 8-hydroxycoumarin, 
and coumarin.[10] XenA shares a generally low amino acid sequence identity and 
similarity with other OYE enzymes and structural variation was observed in the active 
site of XenA compared to the OYE family. A recently published study focused on XenA 
active site residue C25, which replaces the highly conserved threonine residue in OYE 
enzymes. This important residue interacts with FMN and was shown to modulate the 
flavin reduction potential and thus influence substrate binding in XenA.[11] An 
analogous residue C26 in YqjM from Bacillus subtilis (OYE enzyme that shares the 
highest sequence identity and similarity with XenA: 40.1% identity and 53.8% similarity, 
respectively), was shown to act as redox sensor that controls the reduction potential of 
FMN in YqjM, and mutation C26D and C26G changed the enzyme stereoselectivity in 
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the reduction of α,β-unsaturated ketones.[12] Overall, only few mutation studies have 
been published for OYEs[12, 13] to improve their catalytic properties and we wish to 
report efforts toward this goal. 
 
4.2 Results & Discussion 
 In this work, the substrate spectrum, stereoselectivity, and stability of XenA were 
characterized. The selection of mutants was based on the results of iterative saturation 
mutagenesis (ISM) around the binding pocket of YqjM, which implied both residues C25 
and A59 in substrate binding.[12] The QuikChange®  mutagenesis protocol was used to 
generate C25G, C25V, and A59V mutants. We analyzed wild type XenA (WT) and the 
effect of mutations on thermal and chemical stability, enzyme activity, and regio- and 
stereoselectivity with various α,β-unsaturated compounds and nitro compounds (Table 
4.2). Constant cofactor concentration was maintained using a recycling system with 
glucose dehydrogenase (GDH) in conversion study (Fig 4.1). The reaction products were 
extracted and analyzed by gas chromatography to determine substrate conversion and 
product enantiopurity. Enzyme activities were monitored on a spectrophotometer for 










Table 4.1. XenA specific activity and stability study. 
XenA Constructs WT C25G C25V A59V 
Substrate Specific Activity [U/mg] 
1-Nitrocyclohexene 5.87 0.86 0.35 0.16 
2-Cyclohexenone 3.84 0.80 0.47 0.05 
Ketoisophorone 1.34 0.21 0.70 0.02 
2-Methylfuran 0.15 0.16 0.07 0.02 
Tm [°C] 50.4 52.7 48.0 63.5 
t1/2 at 37°C [h] 63 49.5 44.7 >112 
kd,obs [h
-1
] 0.0119 0.0136 0.0155 <0.0062 










 Specific activity assay: 200 mM phosphate buffer pH 7.5, 1 mM substrate, 0.2 mM 
NADPH, 10 µg.mL
-1
 (0.25 µM) enzyme, 37 
ο
C. t1/2 assay: Enzymes incubated at 37 
ο
C 
and residual activity measured with 2-cyclohexenone at different time points.   
 
4.2.1 Specific activity study of XenA   
 The enzymatic activity of XenA and mutants was first investigated on four 
different substrates: 1-nitrocyclohexene, 2-cyclohexenone, ketoisophorone, and 2-
methylfuran. WT showed highest specific activity compared to all other mutants on the 
four compounds. Both C25 mutants showed significantly lower reactivity for all 
substrates with < 1 U.mg
-1
 specific activities observed. Mutation on the C25 residue was 
previously shown to strongly affect both oxidative half reaction towards the substrate and 
reductive half reaction towards the cofactor.[11] Our results confirmed the importance of 
C25 in the overall reaction as shown by the much lower specific activity of the mutants 
compared to the wild type. Mutation of A59V had a dramatic effect on XenA, as it almost 
led to disappearance of any enoate reductivity. We also observed uncompetitive substrate 
inhibition with 2-cyclohexenone; inhibition has never been observed with XenA 
before.[10, 11] A non-linear fit of the Michaelis-Menten equation yielded kcat of 25.7 s
-1
, 
KM of 0.19 mM, and inhibition constant KI of 0.15 mM.   
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 Substrate inhibition was observed with substrate 2-cyclohexenone with 
uncompetitive inhibition pattern. Concentration activity profile range (0 - 2.5 mM) was 
fitted with Matlab to determine the inhibition constant, KI: 
 
Michaelis-Menten equation for uncompetitive inhibition:  
where  
 
Note: ν0 is the initial reaction rate at substrate concentration [S], Vmax is the maximum 
rate, Michaelis constant KM measures the substrate concentration at half Vmax, KI is the 
inhibition constant, and [I] is the inhibitor concentration. 




























Figure 4.2. Michaelis-Menten fit for 2-cyclohexenone (0 – 2.5 mM) substrate inhibition 
with XenA.  
The fitted parameters were: kcat = 25.7 s
-1
, KM = 0.19 mM, KI = 0.15 mM, R
2





4.2.2 Kinetics and thermal deactivation  
 XenA kinetic measurement was performed by monitoring the oxidation of 
cofactor NADPH at 340 nm using spectrophotometer (Beckman Coulter DU800, Brea, 




. Assay condition: 200 mM 
phosphate buffer pH 7.5, 1 mM substrate, 0.2 mM cofactor NADPH, 10 µg.mL
-1
 enzyme, 
at 37 °C. Enzyme thermostability study (half-life t1/2) was performed with incubation of 
purified enzyme at 37 °C, and monitoring the residual activity with 2-cyclohexenone 
kinetic assay over time. The collected data was fitted with 1
st
 order deactivation kinetic to 
determine the deactivation constant, kd,obs. The half-life t1/2 at 37 °C results: wild type 63 
h, C25G 49.5 h, C25V 44.5 h, A59V >112 h. The deactivation constant kd,obs results: wild 
type 0.0119 h
-1
, C25G 0.0136 h
-1
, C25V 0.0155 h
-1
, A59V 0.0062 h
-1




 order deactivation equation:  
Linearization:  
Half life equation:  
 
Note: [A] is the enzyme concentration at time t, [A]0 is the original enzyme 
concentration, t is time measurement, t1/2 is the half-life, and kd,obs is the deactivation 
constant.  







Figure 4.3. Thermal deactivation study of XenA wild type, C25G, and C25V mutants. 
 83 
 Due to its relatively high sequence identity with YqjM, XenA belongs to the same 
subclass of OYEs that has been proposed to contain “thermostable-like” enzymes along 
with recently identified thermostable OYE from T. pseudethanolicus,[14] and chromate 
reductase from the thermophile T. scotoductus.[15] One characteristic of this subclass is 
the conservation of C25, which was observed in both XenA and YqjM. We investigated 
the effect of C25 mutation on the thermal stability by measuring both the melting 
temperature (Tm) and the half-life (t1/2) 37 °C. The Tm of WT was determined to be 50.4 
°C with t1/2 of 58.2 hours at 37 °C. C25G displayed a slightly higher Tm (52.7 °C) but a 
lower t1/2 (50.9 h), whereas C25V showed opposite behavior with Tm (reduced to 48.0°C) 
and a significantly lower t1/2 of 44.7 hours. (Table 4.1) Surprisingly, A59V mutant 
showed major improvement in Tm to 63.5 °C and consequently higher t1/2 at 37 °C. XenA 
and YqjM were proposed to be stabilized through simple salt bridges involving single 
pairs of charged amino acids.[16] However, the single A59V mutation showed significant 
influence on thermostability (although as an uncharged residue, it cannot form any salt 
bridge), while the C25 residue did not show significant influence on thermostability. 
 The melting temperature Tm was determined with Circular Dichroism 
Spectropolarimeter (Jasco-810, Easton, MD) using 6Q quartz cuvette by analyzing the 
change in ellipticity at 220 nm. CD measurement assay: enzyme concentration at 50 
µg.mL
-1
 with temperature ramp of 1 °C.min
-1
 from 20 – 90 °C. The data was interpreted 
employing a two-state model with a native and a denaturated state. 
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XenA WT Tm Curve
Melting Temp = 50.4206 C
Delta H = -2.1312e+005
Rsq = 0.9789









XenA C25G Tm Curve 
Melting Temp = 52.6676 C
Delta H = -1.3835e+005
Rsq = 0.9817









XenA C25V Tm Curve
Melting Temp = 47.9807 C
Delta H = -2.0948e+005
Rsq = 0.9827









XenA A59V Tm Curve
Melting Temp =  63.5679 C
Delta H = -1.3633e+005
Rsq = 0.9858
 
Figure 4.4. Tm curve for XenA WT, C25G, C25V, and A59V mutants.  
α = 1 represents enzyme was at native state, α = 0 represents enzyme at denatured state. 
The Tm result: wild type 50.4 °C, C25G 52.7 °C, C25V 48.0 °C, and A59V 63.5 °C. 
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4.2.3 Total turnover number study 
 The total turnover number (TTN) is an indicator of lifetime biocatalyst 
productivity and is defined as the maximum number of molecules of substrate that an 
enzyme active site can convert over its life cycle. The chemical TTN (TTNchem)[17, 18] 
was experimentally determined by measuring the maximum amount of substrate 2-
cyclohexenone that can be reduced with a set amount of purified enzyme before the 
enzyme is chemically deactivated. The thermal TTN (TTNthermal) was based on the 
thermal deactivation of enzyme, calculated from the ratio kcat/kd,obs , valid for enzymes 
with 1
st
 order thermal deactivation,[19] such as XenA. The WT showed the highest TTN 
values compared to all other variants. Mutant A59V showed the lowest TTNchem of 38 
and TTNthermal of 1.9×10
4
. Overall, the results showed that XenA enzyme reactivity was 
dominated by chemical rather than thermal deactivation, and that single point mutations 
on C25 and A59 led to significant decrease in TTN. The cause for the chemical turnover-
dependent deactivation is under investigation. Turnover-driven stability limits have also 
been observed in D-amino acid oxidase in connection with the mutation of the C108 
residue.[20] 
Chemical TTN was determined by varying the enzyme concentration and 
observing NADPH turnover until no more turnover (i.e. change in NADPH 
concentration) was observed.  
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Figure 4.5. TTN Data for XenA WT and mutants. α defined as  the amount of cofactor in 
the system. Assay: 200 mM phosphate buffer pH 7.5, 0.2 mM NADPH, 2 mM 2-
cyclohexenone, and varying amount of enzyme at 37 °C. The TTNchem results: wild type 
1959, C25G 1073, C25V 280, and A59V 38 (Table 4.1). Note: TTNchem for A59V is an 
approximation, this mutant still show activity even after >10 h of measurement.  
  
 Thermal TTN was estimated from readily measured biochemical quantities, 
namely the specific activity and the deactivation half-life, measured under identical 
conditions at 37 °C. This method was established and proved in recent work for enzymes 
whose thermal deactivation followed the 1
st
 order deactivation.[19] This estimation 
method requires two parameters, namely kd,obs, the observed first-order deactivation rate 









The process yield during the life time of a biocatalyst: 
 
where we define:  
The integrated result gave:  
where  
and  
Note: [E]0 is the original enzyme concentration, kcat,obs is the observed catalytic constant, 









 (Table 4.1) 
 
4.2.4 Biocatalytic conversion of various α,β-unsaturated carbonyl, nitrostyrene, 
nitroaromatic, and nitrofuran substrates  
 The conversion study of XenA was performed over 12 hours with multiple sets of 
substrate: α,β-unsaturated carbonyl compounds (1 - 5), α,β-unsaturated nitro compounds 
(6 – 9), nitro aromatic compounds (10 – 11), and nitrofuran-like substrate (12 – 14) 
(Table 4.2). This is the first study where nitrofuran type substrates are tested with true 
OYE enzymes. The WT showed high conversion efficiency in C=C reduction of substrate 
2, 4, and 9; and modest conversion for substrate 2, 10, and 12. The WT also showed 
moderate to excellent stereoselectivity for reduction of 2 (78.5% R), 5 (99.5% R), and 6 
(69.9% S), although a racemic product was obtained in the reduction of 4 (2.25% S).[21] 
Overall, the WT seems to show preference for cyclic compounds (except 2 and 3). 
Mutation C25G improved the conversion and stereoselectivity with various substrates 
compared to the wild type: conversion of 3 was increased to 6.4% from 0.4% with 
product e.e >99.9% (R); conversion of 5 was increased fourfold with similar product e.e; 
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conversion of 6 was also improved by 4-fold to 33.3% with slight improved product e.e. 
Most importantly, one single mutation was able to significantly increase the conversion 
of 11 (5 mM) from 1.1% to 54.3% to produce nitrosobenzene (0.18 mM), aniline (0.15 
mM), and azobenzene (2.6mM). C25V mutant showed higher conversion efficiency of 
substrate 2 and 5 with similar or slightly enhanced product e.e; conversion of substrate 6 
was slightly improved, the product was however nearly racemic with e.e of 2.7% (S); 
C25V also catalyzed the reduction of 11 and produced similar products as C25G mutant, 
including aniline. Mutant A59V showed lower conversion for most of the tested 
substrates. However, the stereoselectivity in the reduction of 6 was significantly 
improved to 98% (S) while maintaining similar conversion efficiency as WT. Upon this 
result, we analyzed the reduction of 6 with the double mutant C25G/A59V. However, 
C25G/A59V showed negligible activity, even with 2-cyclohexenone as substrate. All 
mutants showed highly reduced enzymatic activity towards the reduction of nitrofurans 
(12 – 14), except for A59V that retained activity towards 13. 
 Both single mutants C25G and C25V surprisingly catalyzed the reduction of 6 to 
produce aniline, while WT was nearly inactive. A similar reduction pattern was also 
reported for NRSal from S. typhimurium.[22] We propose the removal of the C25 residue 
changes the binding conformation of 6 in the catalytic pocket, thus allowing the 
subsequent reduction of the nitro group via two-electron reduction pathway and the 
formation of aniline. Traces of phenylhydroxylamine were also observed along the 
enzyme-catalyzed formation of aniline. Formation of azobenzene as side product was 




Table 4.2. Biocatalytic conversion of various α,β-unsaturated carbonyl, nitrostyrene, nitroaromatic, and nitrofuran substrates. 
Substrate XenA WT C25G C25V A59V 
  Conv. e.e Conv. e.e Conv. e.e Conv. e.e 
1. 2-Cyclohexenone 96.4% - 99.1% - 21.5% - 7.1% - 
2. 2-Methyl-2-cyclopentenone 19.7% 78.5% (R) 12.9% 59.9% (R) 32.4% 86.1% (R) 0.5% - 
3. 3-Methyl-2-cyclohexenone 0.4% n.dc 6.4% >99.9% (R) 0.9% n.d 
no 
conv. - 
4. Ketoisophorone 98.9% 2.25% (S) 54.1% 37.7% (S) 87.7% 14.9% (S) 3.8% 25.6% (S) 
5. Citral 8.1% 99.5% (R) 33.5% 99.5% (R) 18.5% 99.3% (R) 18.4% 68.0% (R) 
6. 1-Nitro-2-phenyl-propene
a
 7.1% 69.9% (S) 33.3% 72.9% (S) 11.7% 2.7% (S) 6.3% 98% (S) 
7. Trans-β-nitrostyrene 10.1% - 15.6% - 
no 
conv. - 5.0% -    
8. Trans-β-methyl-β-
nitrostyrene 13.6% - 36.1% - 2.7% - 3.6% - 
9. 1-Nitrocyclohexene 91.2% - 29.3% - 53.2% - 
no 
conv. - 
10. 2,4-Dinitrotoluene 60.2% - 59.9% - 23.2% - 6.6% - 
11. Nitrobenzene
b
 1.1% - 54.3% - 5.9% - 
no 
conv. - 
12. 2-Nitrofuran 47.0% - 0.7% - 1.3% - 5.8% - 
13. 2-Methyl-5-nitrofuran 17.4% - 5.8% - 7.0% - 22.9% - 
14. 2-(2-Nitrovinyl)-furan 8.3% - 7.9% - 9.3% - 5.8% - 
        
 
Conversion assay: 200 mM phosphate buffer pH 7.5, 5mM substrate, 20µg.mL
-1
 (0.5 µM) enzyme, 0.2 mM NADP
+





The conversion of  6 showed side products other than 1-nitro-2-phenyl-propane, which are possibly the 
corresponding carbonyl compounds similar to Nef-reaction products.[24] 
b.
Conversion of 11 with C25G and C25V produced 
nitrosobenzene, aniline, and azobenzene. 
c.




 In conclusion, we have characterized the substrate spectrum of WT XenA and 
mutants. The enzyme showed a high degree of conversion and marked stereoselectivy 
and was able to reduce C=C bonds as well as nitro compounds. Mutations on C25 
interestingly showed significantly stronger nitroreductase activity to produce the 
corresponding amino product. We also studied both chemical and thermal enzyme 
stability, melting temperature, and TTN as an indicator for biocatalyst productivity. The 
results showed the effect of chemical instability is more significant than thermal 
instability. 
 
4.4 Materials & Methods 
4.4.1 XenA expression and purification  
 The gene of XenA from Pseudomonas putida was kindly provided by Prof. Brian 
Fox (University of Wisconsin, Madison, WI).
1
 The xenA gene was transformed into E. 
coli BL21 for protein expression. The culture was started in a 5 mL LBKan medium 
inoculated from frozen glycerol stock and grown overnight at 37 °C. The preculture was 
used for inoculation of a 1 L culture (0.1% v/v), which was gently aerated until OD600 
reached 0.6 before addition of 0.1 mM of IPTG. The induced culture was incubated 
overnight for protein expression at 37 °C. Harvested cell pellets were kept at -80 °C 
before protein purification.  
 XenA was purified with a two-step column purification process: HiTrap Q-XL 
anion chromatography and HiPrep Sephacryl S-100 gel filtration chromatography on an 
Ä KTAexplorer
TM
 system (all by GE Healthcare, Sweden). The harvested XenA pellet 
was first resuspended in 20 mM pH 8.0 bis-tris buffer and disrupted by sonication. The 
cell debris were discarded by centrifugation, and the supernatant was washed with a 
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gradient of 0 - 500 mM KCl in 20 mM bis-tris buffer on a Q-XL column at a flow rate of 
1 mL/min. The majority of XenA eluted at 300 mM KCl and was applied to the 
Sephacryl S-100 column. 50 mM sodium phosphate buffer with 300 mM NaCl at pH 7.5 
was used as the running buffer with flow rate set at 0.5 mL/min, where pure XenA was 
collected at 60 – 70 mL elution range (total column volume is 120 mL). The protein 
concentration was determined by the Bradford method using Coomassie Plus Protein 
assay reagent with BSA assay (Pierce Chemical) as the calibration curve standard. SDS-
PAGE analysis was performed with 50 µg protein loaded into each well (Figure 4.6). The 
protein samples were mixed with 2X sample buffer (125 mM TrisHCl, pH 6.8, 4% SDS, 
50% glycerol. 0.02% bromophenol blue, and 10% 2-mercaptoethanol). The mixed 
samples were incubated at 100°C for 5min and loaded onto 12% PAGE
TM
 Gold precast 
gel and run in BioRad Mini Protean chamber (BioRad,Hercules CA) at 150 V for 45 min 
with Tris-HEPES-SDS running buffer (12.1 g/L Tris, 23.8 g/L HEPES, 1 g/L SDS). 
Biorad Precision Plus protein ladder was used as standards in the gel analysis. GelCodeR 
Blue Stain Reagent (Pierce, Rockford IL) was used for final gel staining. Lastly, we 
measured the FMN occupancy of the purified XenA (all purified XenA wild type and 
variants showed full FMN occupancy) and checked the enzymatic activity with 2-
cyclohexenone as substrate (Table 4.3). The FMN occupancy study was performed by 
observing the changes in XenA at both 360 nm and 450 nm wavelength for native and 
unfolded states. The changes in absorbance were used to compute the FMN concentration 




. The occupancy of FMN was determined 




Figure 4.6. SDS-PAGE analysis for wild type XenA purification. Lane #1 lysate, #2 Q-
XL fraction, #3 S-100 fraction. 
 













Lysate 38.4 100 2.56 98.3 100 
QXL Fraction 13.3 34.6 2.97 39.5 40.2 
S-100 Fraction 3.81 9.91 3.84 14.6 14.9 
Assay: 200 mM phosphate buffer pH 7.5, 1 mM 2-cyclohexenone, 0.2 mM NADPH, 
37°C, and 10 µg of enzyme. 
 
4.4.2 QuikChange®  mutagenesis protocol  
 The mutations on XenA were accomplished with the QuikChange®  mutagenesis 
protocol with the following PCR primers design (red letters indicate the changes to the 
wild type): 
C25G: Forward: 5' CGCCATTCCGCCCATGGGCCAGTACATGGCCGAGGAT 3' 
C25V: Forward: 5' CATCGCCATTCCGCCCATGGTGCAGTACATGGCCGAGGATGG 3' 
A59V: Forward: 5' TGGTGGTCGAAGCCACGGTGGTGGCACCGGAAGGGC 3' 
 
 The xenA gene from Pseudomonas putida in pET27 vector was used as the 
template for mutations. Failsafe buffer J (EPICENTER
®
 Biotechnology, Madison, WI) 
was used in the standard PCR protocol with Pfu polymerase from New England Biolabs 
(Marlborough, MA). PCR assay: 25 µL of Failsafe buffer J, 125 ng xenA DNA plasmid 
template, 0.25 µM each of both forward and reverse primers, and sterile water to 50 µL 
in total volume. The mixed sample was first denatured at 98 °C for 5 minutes, 














supplemented with 1 µL of Pfu buffer, followed by denaturation at 98 °C for another 30 
seconds. The annealing temperature was set at 55 °C for 1 minute, extension at 72 °C for 
16 minutes, and repeated for total of 18 cycles. The final extension was set at 72 °C for 
25 minutes, and finished with temperature hold at 4 °C. All mutants were sequenced with 
Eurofins MWG Operon (Birmingham, AL) service and transformed into E. coli BL21 
strain for protein expression and purification as described in Section 1.1.    
 
4.4.3 Gas chromatography analytical procedures   
 GC-FID analyses were performed on a Shimadzu GC-2010 instrument with 
helium (ultra high purity grade, Airgas South, Atlanta, GA) as carrier gas. Conversions of 
compounds 1–14 and e.e. values of the corresponding products were determined with the 
columns and methods described below. All the substrates and the corresponding products 
were purchased from Sigma Aldrich unless stated otherwise with literature resources 
provided.  
 2-Cyclohexen-1-one (1), trans-β-nitrostyrene (7), trans-β-methyl-β-nitrostyrene 
(8), 1-nitro-1-cyclohexene (9), 2,4-dinitrotoluene (10), nitrobenzene (11), 2-nitrofuran 
(12), 2-methyl-5-nitrofuran (13), and 2-(2-nitrovinyl)-furan (14) were analyzed using a 
SHRX5 column (15 m, 0.25 mm, 0.25 µm) (Shimadzu, Kyoto, Japan). Temperature 
program for 1: injector and detector temperature at 220 °C; split ratio 25:1; start at 100 
°C, hold 2 min, 10 °C.min
-1
 to 160 °C, hold 2 min. Retention time: 2-cyclohexen-1-one 
1.4 min, cyclohexanone 1.3 min. Temperature program for 7: injector and detector 
temperature at 320 °C; split ratio 25:1; start at 100 °C, hold 2 min, 10 °C.min
-1
 to 180 °C, 
20 °C.min
-1
 to 180 °C, hold 1 min. Retention time: trans- β -nitrostyrene 6.5 min. 
Temperature program for 8: injector and detector temperature at 320 °C; split ratio 25:1; 
start at 100 °C, hold 2 min, 10 °C.min
-1
 to 180 °C, 20 °C.min
-1
 to 180 °C, hold 1 min. 
Retention time: trans-β-methyl-β-nitrostyrene 6.5 min. Temperature program for 9: 
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injector and detector temperature at 220 °C; split ratio 25:1; starting at 100 °C, hold 1 
min, 20 °C.min
-1
 to 220 °C, hold 1 min. Retention time: 1-nitro-1-cyclohexene 8.2 min, 
nitrocyclohexane 16.3 min. Temperature program for 10: injector and detector 
temperature at 300 °C; split ratio 25:1; starting at 80 °C, hold 2 min, 15 °C.min
-1
 to 290 
°C, hold 4 min. Retention time: 2,4-dinitrotoluene 8.1 min. Temperature program for 11: 
injector and detector temperature at 300 °C; split ratio 25:1; starting at 80 °C, hold 5 min, 
10 °C.min
-1
 to 290 °C, hold 5 min. Retention time: nitrobenzene 5.6 min, aniline 3.2 min, 
nitrosobenzene 2.2 min, azobenzene 14.1 min, phenylhydroxylamine 8.0 min. 
Temperature program for 12: injector temperature at 150 °C and detector temperature at 
220 °C; split ratio 25:1; starting at 50 °C, hold 3 min, 30 °C.min
-1
 to 200 °C, hold 2 min. 
Retention time: 2-nitrofuran 4.6 min. Temperature program for 13: injector temperature 
at 150 °C and detector temperature at 220 °C; split ratio 25:1; starting at 50 °C, hold 3 
min, 30 °C.min
-1
 to 200 °C, hold 2 min. Retention time: 2-methyl-5-nitrofuran  6.1 min. 
Temperature program for 14: injector temperature at 150 °C and detector temperature at 
220 °C; split ratio 25:1; starting at 50 °C, hold 3 min, 30 °C.min
-1
 to 200 °C, hold 2 min. 
Retention time: 2-(2nitrovinyl)-furan 6.4 min.  
 Compounds 2-methyl-2-cyclopentenone (2), 3-methyl-2-cyclohexenone (3), 
ketoisophorone (4), and citral (5) were analyzed using Rt-BDEXcst chiral column (30 m, 
0.32 mm, 0.25 µm) (Restek, Bellefonte, PA). Temperature program for 2: injector and 
detector temperature at 200 °C; split ratio 25:1; start at 70 °C, hold 8 min, 10 °C.min
-1
 to 
80 °C, hold 2 min, 30 °C.min
-1
 to 180 °C, hold 5 min. Retention time: 2-methyl-2-
cyclopentenone 16.3 min, (R)-2-methylcyclopentanone 15.5 min, (S)-2-
methylcyclopentanone 15.4 min. The absolute configurations of the enantiomers were 
determined via CD method as described in literature.[25] Temperature program for 3: 
injector and detector temperature at 200 °C; split ratio 20:1; start at 90 °C, 1 °C.min
-1
 to 
130 °C, 5 °C.min
-1
 to 180 °C, hold 10 min. Retention time: 3-methyl-2-cyclohexenone 
50.7 min, (R)-2-methylcyclohexanone 37.4 min, (S)-3-methylcyclohexanone 37.6 min. 
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Temperature program for 4: injector and detector temperature at 210 °C; split ratio 25:1; 
start at 100 °C, 3 °C.min
-1
 to 130 °C, 20 °C.min
-1
 to 200 °C, hold 3 min. Retention time: 
ketoisophorone 15.4 min, (R)-levodione 15.9 min, (S)-levodione 15.7 min. Temperature 
program for 5: injector and detector temperature at 210 °C; split ratio 6.4:1; start at 80 
°C, 2.5 °C.min
-1
 to 130 °C, hold 10 min, 5 °C.min
-1
 to 180 °C, hold 5 min. Retention 
time: citral 31.2 min, (R)-citronellal 22.1 min, (S)-citronellal 21.9 min.  
 1-Nitro-2-phenylpropene (6) was analyzed using Cyclosil-B chiral column (30 m, 
0.32 mm, 0.25 µm) (Agilent J&W Scientific, Santa Clara, CA). Temperature program for 
6: injector and detector temperature at 210 °C; split ratio 25:1;  start at 100 °C, hold 10 
min,  5 °C.min
-1
 to 130 °C, hold 15 min, 5 °C.min
-1
 to 220 °C, hold 2 min. Retention 
time: 1-nitro-2-phenylpropene 28.7 min and 35.3 min (isomers), (R)-1-nitro-2-
phenylpropane 25.0 min, (S)-1-nitro-2-phenylpropane 24.7 min. The substrate synthesis 
and product identification were accomplished with the reported method.[1] 
 
4.5 Publication Information 
 The work presented in Chapter 4 of this dissertation was published in the 
Chemical Communications, volume. 46 pages 8809-8811, 2010; with Hua-Hsiang Yu, 
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ASYMMETRIC BIOREDUCTION OF ALKENES USING YERS-ER 
AND KYE1, AND EFFECTS OF ORGANIC SOLVENTS 
 
 Asymmetric trans-bioreduction of activated alkenes by KYE1 from 
Kluyveromyces lactis and YersER from Yersinia bercovieri, two ene-reductases from the 
Old Yellow Enzyme Family, showed broad substrate spectrum with a moderate to 
excellent degree of stereoselectivity. Both substrate- and enzyme-based stereocontrol 
were observed to furnish opposite stereoisomeric products. The effects of organic 
solvents on enzyme activity and stereoselectivity were outlined in this study, where two-
phase systems hexane and toluene are shown to sustain bioreduction efficiency even at 
high organic solvent content. 
 
 
Figure 5.1. Enzyme and substrate based stereocontrol asymmetric trans-bioreduction of 






 The application of biocatalyst has become an increasingly attractive route in the 
production of enantiomerically pure compounds in industry due to exquisite regio- and 
stereoselectivity.[1, 2] One of the emerging platforms is the asymmetric reduction of 
activated C=C bonds due to the potential to create up to two new stereogenic centers in 
the process.[3-7] Ene-reductase from the Old Yellow Enzyme (OYE) family have been 
reported to catalyze the reduction of a variety of different substrates such as α,β-
unsaturated compounds (activated by electron-withdrawing groups such as aldehydes, 
ketones, imides, nitro groups, nitriles, carboxylic acids, esters) and nitro derivatives such 
as nitro esters and nitro aromatics.[8-11] The reduction reaction catalyzed by the OYE 
family of flavoproteins proceeds in a strict trans fashion, with hydride attack derived 
from the nicotinamide cofactor.[12, 13] Utilizing the coupled-enzyme approach, an 
efficient cofactor recycling system with enzymes such as glucose dehydrogenase (GDH) 
is commonly applied to decrease the high costs of redox cofactor for larger scale 
synthesis.[4, 14, 15] Furthermore, a light-driven cofactor regeneration system[16] and a 
nicotinamide-independent reduction system[17] were recently reported to yield high 
substrate conversion and product enantiopurity; again highlighting the potential of OYEs 
in industrial biotechnological applications.  
 In a previous work, we have begun to characterize three ene-reductases: KYE1 
from Kluyveromyces lactis, YersER from Yersinia bercovieri, and XenA from 
Pseudomonas putida. We have shown that these three ene-reductases feature broad but 
different substrate specificity on various α,β-unsaturated carbonyl compounds. XenA was 
further demonstrated to possess moderate to excellent stereoselectivity and catalyze the 
reduction of various nitro compounds.[18, 19] In this study, we further explore the 
catalytic efficiency and stereoselectivity of YersER and KYE1 with a new set of 
substrates including α,β-alkyl substituted cyclic enones, enolethers, carboxylic esters, 
 101 
nitrostyrenes, and maleimide-type compounds, and test both enzymes in aqueous-organic 
media.   
 
5.2 Results & Discussion 
5.2.1 Asymmetric bioreduction of alkenes 
 The substrate study for both KYE1 and YersER were performed over 12 hours 
with the GDH cofactor recycling system (Table 5.1). Both enzymes showed excellent 
stereoselectivity toward the reduction of α,β-alkyl substituted cyclic enones (1 - 4), and 
predominantly furnished the corresponding (S)-products. Substrate-based stereocontrol 
was observed for the reduction of α,β-substituted enolethers[20]. The reduction of five-
membered cyclic-enolethers (5-6) furnished the corresponding (S)-products, but 
increasing the ring-size to cyclohexenone-enolether (8), the stereopreference  switched to 
(R) for both enzymes; furthermore, by changing the side chain substitution from a methyl 
group (8) to a sterically more demanding n-propyl- (10) or phenylgroup (9), the substrate 
was flipped in the enzyme binding pockets to furnish the corresponding (S)-products. The 
results from substrates 1 – 13 showed that KYE1 and YersER strongly prefer α-
substituted substrates, significantly lower activity was observed for β-substituted 
substrates (2, 4, 7, 11, and 13). The conversion of dicarboxylic esters, nitrostyrenes, 
maleimide, and citral (14 – 21) revealed moderate to high degree of enzymatic activity 
together with excellent product enantiopurity, except for 19, where a racemic product was 
observed for both enzymes.[5] Enzyme based stereo-control was again seen in the 
reduction of 15 and 21, where KYE1 and YersER formed the corresponding (R)- and (S)-





Table 5.1. Asymmetric bioreduction study using ene-reductase KYE1 and YersER. 
 
Enzyme  KYE1 YersER 
  Conv % e.e % Conv % e.e % 
α,β-alkyl substituted cyclic enones 
1. R1 = CH3, R
2
 = H 
1-2  
65 (S) >99 45 (S) >99 
2. R1 = H, R
2
 = CH3 6 (S) >99 3 (S) >99 
    
    
3. R1 = CH3, R
2
 = H 
3-4  
89 (S) >99 95 (S) >99 
4. R1 = H, R
2
 = CH3 27 (S) >99 5 (S) >99 
α,β-substituted enolethers 
5. R1 = CH3 
5-6 , 7  
46 (S) 90 51 (S) 47 
6. R1 = CH2Ph 0.4 (S) >99 26 (S) 99 
7. R1 = CH3 nc
a - nc - 
8. R1 = CH3 
8-10 , 11  
54 (R) 71 68 (R) 32 
9. R1 = CH2Ph 29 (S) 90 100 (S) 92 
10. R1 = CH2CH2CH3 1 (S) >99 68 (S) 94 
11. R1 = CH3 0.5 - nc - 
Monoesters      
12. R1 = H 
12-13  
39 - 42 - 
13. R1 = CH3 nc - nc - 
Dicarboxylic esters 
14 
14 , 15  
 
 16  
74 (R) 97 87 (R) >99 
15 89 (S) 94 79 (R) 77 
16 3 (R) >99 29 (R) >99 
Nitrostyrene 
17. R1 = H, R
2
 = H 
17-19  
100 - 100 - 
18. R1 = CH3, R
2
 = H 98 (R) 95 98 (R) 99 
19. R1 = H, R
2








68 (R) 86 96 (S) >99 
 
 
5.2.2 Effects of organic solvents on catalytic efficiency and stereoselectivity  
To enhance the technological utility of ene-reductase for gram-scale synthesis, 
especially for less water-soluble substrates, we investigated the effects of organic 
solvents on catalytic efficiency and stereoselectivity. To date, there are only few data 
published addressing solvent effects on OYEs,[22, 23] and
 
this work represents the first 
detailed study of organic solvent effects on ene-reductase. Water/organic binary co-
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solvent systems often enhance the catalytic properties of enzymes and potentially offer 
significant advantages for increasing biocatalyst performance in synthetic chemistry.[24, 
25]
 
Twelve different organic solvents (both water miscible and immiscible), arranged 
according to denaturation capacity scale,[26] were tested with KYE1 and YersER for the 
bioreduction of 2-cyclohexen-1-one in 20% organic solvent / buffer system (Table 5.2).  
 







 YersER KYE1 
   Conv % Conv % 
Ethylene glycol 18.7 -1.43 100 98.9 
Methanol 30.5 -0.74 61.8 23.7 
1,2-Propanediol 38.8 -0.74 3.1 3.2 
Ethanol 54.4 -1.35 6.9 6.6 
Dimethyl sulfoxide 60.3 -0.32 100 98.5 
Dimethylformamide 63.3 -1.35 5.1 4.1 
Acetonitrile 64.3 -0.32 0.6 0.2 
Acetone 78.2 3.5 9.8 5.3 
1,4-Dioxane 92.1 -0.27 10.7 9.1 
Tetrahydrofuran 100 0.46 1.0 0.7 
Toluene 137.9 2.46 98.1 97.8 
Hexane 144.4 3.5 94.8 95.3 
 
 
Screening results showed that both KYE1 and YersER retained highest enzyme 
activity in ethylene glycol, dimethyl sulfoxide (DMSO), and in the hexane- and toluene-
buffer systems. Given the low level of amino acid identity and similarity between KYE1 
and YersER (36% and 53%, respectively), the result also suggests that, in this case, the 
effect of organic solvents on enzyme stability is independent of both the denaturing 
capacity scale and the protein amino acid sequences. The experimentally determined 
threshold concentration (C50), at which half inactivation of the enzyme is observed, for 
both KYE1 and YersER was 43.3% for ethylene glycol/buffer and 27.5% for dimethyl 
sulfoxide/buffer. For the two-phase hexane and toluene systems, the catalytic reaction 
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does not seem to be impaired even at 70% organic solvent level, corresponding to a phase 
ratio of organic to aqueous solvent of 2.33 (0.7:0.3). Since both hexane and toluene are 
immiscible with water, the enzymes are expected to be in the aqueous phase with 
minimum contact of organic solvents, and thus retained full enzyme activity. However, 
there is only one phase for ethylene glycol and DMSO systems, therefore the enzymes 
were much more exposed to the organic solvent, which resulted in decreased activity. A 
similar trend was observed for the bioreduction of citral with KYE1 and YersER, where 
the conversion and product enantiopurity were monitored in the presence of 0 – 50% 
organic solvent (Figure 5.2). Surprisingly, the product enantiopurity decreased tracking 
the diminishing enzyme activity (lower conversion) for ethylene glycol (Fig 5.2a) and 
DMSO (Fig 5.2b). The hexane- and toluene-buffer systems again showed constant 
enzymatic activity and product enantiopurity in the investigated range of phase ratio (Fig 






Figure 5.2. Dependence of organic solvent concentration on the catalytic activity and 













5.2.3 YersER and KYE1 denaturation studies  
The denaturation process of KYE1 and YersER by a series of organic solvents of 
different nature was investigated in this study based on the bioconversion results were 
analyzed by gas chromatography. Ethylene glycol and dimethyl sulfoxide systems 
showed that the denaturation proceeded in an S-curve-type trend, with a rapid change in 
enzyme catalytic activity observed after a certain threshold concentration of organic 
solvent had been reached (Fig 5.3a-b). The experimentally determined threshold 
concentration (C50) for both KYE1 and YersER was 43.3% for the ethylene glycol system 
and 27.5% for the dimethyl sulfoxide system. The C50 of enoate reductases appeared to 
be higher for systems with lower denaturing capacity (DC) factor such as ethylene glycol 
(DC 18.7), compared to dimethyl sulfoxide (DC 60.3).  For hexane and toluene systems, 
the catalytic activities of both enzymes were not impaired. The bioconversion both 
enzymes remained constant even at 70% organic solvent level (Fig 5.3c-d).  
 
Figure 5.3. Dependence of catalytic activity of KYE1 (∆) and YersER (X) on the 
concentration of organic solvents for bioreduction of 2-cyclohexen-1-one. 
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5.3 Conclusion 
In conclusion, KYE1 and YersER showed broad substrate spectrum with a 
moderate to excellent degree of stereoselectivity. The results displayed both substrate-
based (enolethers, diesters) and enzyme-based (citral, lactones) stereocontrol. Biphasic 
organic solvent / buffer system revealed no effect of the phase ratio (in the range of 0 – 
2.3) on catalytic efficiency or stereoselectivity. In monophasic DMSO- and ethylene 
glycol-buffer systems, the activity declined markedly beyond 20% and 35% solvent, 
respectively, and stereoselectivity of citral bioconversion declined as well with rising 
solvent content. To further enhance the applicability of ene-reductases, future research 
efforts should focus on predictability and effective enhancement of product enantiopurity.   
Acknowledgment: The experimental assistance of Clemens Stueckler and Hua-
Hsiang Yu is gratefully acknowledged.  
 
5.4 Materials & Methods 
5.4.1 Enzyme expression and purification 
KYE1 and YersER genes were isolated from the genomic DNA of Kluyveromyces 
lactis ATCC 8585 and Yersinia bercovieri ATCC 43970 respectively. The gene 
products were cloned into pET28a (+) vector (Novagen, San Diego, CA) at the 
following restriction sites: NdeI and XhoI for KYE1, and NdeI and HindIII for 
YersER. These constructs enabled the expression of mature ER with an N-terminal 
polyhistidine tag for convenient purification. The sequences of KYE1 and YersER are 
accessible from the NCBI databank with accession numbers P40952 and 
ZP_00823209, respectively.[18] 
 The KYE1 and YersER genes were transformed into E. coli BL21 for protein 
expression. The starter culture consisted of 5 ml LBKan, inoculated from frozen stock, 
and grown overnight at 37 °C. The starter culture was then used for inoculation of 
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300 mL culture (0.1% v/v), which was gently aerated until OD600 reached 0.5 for 
addition of 0.1 mM IPTG and then left overnight for protein expression. Harvested 
cell pellets were kept for -80 °C for protein purification. The polyhistidine tagged 
enzymes were purified according to the standard Ni2+-NTA bead protocol from 
Qiagen (Valencia, CA).
 
The protein concentration was determined by the Bradford 
method with Coomassie Plus Protein assay reagent and BSA assay (Pierce Chemical, 
Chicago, IL) as the calibration curve.  
5.4.2 Bioconversion assay 
The bioconversions for substrates 1 – 4, 17 – 19, and 21 were performed with 200 
mM phosphate buffer pH 7.5, 10 mM substrate, 20 µg.mL
-1
 (0.5 µM) enzyme, 0.2 
mM NADP
+
, 20 mM glucose, 10 U.mL
-1
 GDH, at room temperature incubated over 
12 hours. The bioconversions for substrates 5 – 16, and 20 were performed with 50 
mM Tris/HCl buffer pH 7.5, 10 mM substrate, 15 mM NADPH incubated at 30°C 
over 12 hours.  Then an equal volume of ethyl acetate was added for extraction before 
analysis with GC. Substrates 12 and 13 were extracted using toluene. The phosphate 
buffer system was applied in the organic solvent study, where different ratios of 
organic solvents were mixed into the above assay while maintaining the same 
cofactor recycling system during the bioconversion. Substrates and products of 1 – 4, 
17 – 19, and 21 were purchased from Sigma Aldrich or VWR with highest purity 
available. The enantiopurity of products of 1 and 3 were determined with published 
circular dichroism method.[27, 28] Products of 18 and 19 were synthesized according 
to previous published protocols.[29, 30] Substrates and products of 5 – 16, and 20 
were prepared as reported previously, together with absolute configuration 




5.4.3 Analytical procedures 
Reaction assays were analyzed with a Shimadzu GC-2010 HPLC instrument 
using RT-BDEXcsf chiral column (30 m, 0.32 mm, 0.25 µm film, Restek) for entry 1 
– 4, 21; Hydrodex-beta-TBDAc (25 m, 0.25 mm, 0.25 µm film, Macherey-Nagel) for 
entry 5 – 6, 8, and 14 – 16; Chiraldex B-TA (40 m, 0.25 mm, 0.12 µm film, Supelco) 
for entry 9 – 10; HP5 19091J-413 (30 m 0.320 mm 0.25 µm JW Scientific) for entry 
7, 11,  12 – 13, 20;  and Cyclosil-B chiral column (30 m 0.32 mm 0.25 µm, J&W 
Scientific) for entry 17 – 19. The carrier gas for GC was He at 14.5 psi for entry 1 – 
4, 17 – 19, and 21; and H2 at 14.5 psi for entry 5 – 16 and 20. 
Temperature program for 1: injector and detector temperature at 200 °C; split 
ratio 25:1; starting at 70 °C, hold 8 min, 10 °C.min
-1
 to 80 °C, hold 2 min, 30 °C.min
-
1
 to 180 °C, hold 5 min. Retention time: substrate 13.4 min, (S)-product 12.3 min, 
(R)-product 12.4 min. 
Temperature program for 2: injector and detector temperature at 220 °C; split 
ratio 25:1; starting at 80 °C, hold 5 min, 1 °C.min
-1
 to 110 °C, 20 °C.min
-1
 to 200 °C, 
hold 10 min. Retention time: substrate 14.9 min, (S)-product 12.9 min, (R)-product 
13.0 min. 
Temperature program for 3: injector and detector temperature at 220 °C; split 
ratio 20:1; starting at 100 °C, hold 5 min, 1 °C.min
-1
 to 140 °C, 20°C.min
-1
 to 200 °C, 
hold 10 min. Retention time: substrate 30.8 min, (R)-product 20.1 min, (S)-product 
20.3 min. 
Temperature program for 4: injector and detector temperature at 200 °C; split 
ratio 20:1; starting at 90 °C, hold 8 min, 1 °C.min
-1
 to 130 °C, 50 °C.min
-1
 to 180 °C, 
hold 10 min. Retention time: substrate 35.8 min, (R)-product 15.4 min, (S)-product 
15.6 min. 
Temperature program for 5: injector and detector temperature at 200 °C; split 
ratio 20:1; starting at 50 °C, hold 5 min, 10 °C.min
-1




 to 180 °C, hold 10 min. Retention time: substrate 24.5 min, (S)-product 20.7 
min, (R)-product 21.3 min. 
Temperature program for 6: injector and detector temperature at 200°C; split ratio 
25:1; starting at 100 °C, hold 20 min, 10 °C.min
-1
 to 130 °C, hold 30 min, 15 °C.min
-1
 
to 170 °C, hold 20 min. Retention time: substrate 67.0 min, (R)-product 57.6 min, (S)-
product 58.1 min. 
Temperature program for 7, 11, 12 – 13: injector and detector temperature at 200 
°C; split ratio 20:1; starting at 40 °C, hold 2 min, 20 °C.min
-1
 to 180 °C, hold 5 min, 
Retention time: entry 7 substrate 5.9 min, product 4.8 min; entry 11 substrate 8.0 min, 
product 5.8 min; entry 12 substrate 2.5 min, product 2.6 min; entry 13 substrate 3.8 
min, product 3.5 min. 
Temperature program for 8: injector and detector temperature at 200 °C; split 
ratio 25:1; starting at 80 °C, hold 1 min, 2.5 °C.min
-1
 to 100 °C, 15°C.min
-1
 to 180°C, 
hold 5 min. Retention time: substrate 14.6 min, (R)-product 13.5 min, (S)-product 
13.7 min. 
Temperature program for 9: injector and detector temperature at 200 °C; split 
ratio 25:1; starting at 130 °C, hold 40 min, 2 °C.min
-1
 to 180 °C, hold 10 min. 
Retention time: substrate 72.7 min, (R)-product 57.4 min, (S)-product 57.8 min. 
Temperature program for 10: injector and detector temperature at 200 °C; split 
ratio 25:1; starting at 40 °C, hold 2 min, 4 °C.min
-1
 to 120 °C, hold 1 min, 150 
°C.min
-1
 to 180 °C, hold 5 min. Retention time: substrate 27.9 min, (R)-product 23.2 
min, (S)-product 23.5 min. 
Temperature program for 14 - 16: injector and detector temperature at 180 °C and 
200 °C respectively; split ratio 20:1; starting at 90 °C, hold 4 min, 0.5 °C.min
-1
 to 95 
°C, 15 °C.min
-1
 to 130 °C, hold 3 min. Retention time: entry 14 substrate 15.1 min; 
entry 15 substrate 15.5 min, entry 16 substrate 15.1 min, (R)-product 11.8 min, (S)-
product 12.3 min (substrates 14, 15 and 16 yield the same product). 
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Temperature program for 17 - 19: injector and detector temperature at 210 °C; 
split ratio 25:1;  start at 100 °C, hold 10 min,  5 °C.min
-1
 to 130 °C, hold 15 min, 5 
°C.min
-1
 to 220 °C, hold 2 min. Retention time: entry 17 substrate 25.3 min, product 
19.0 min; entry 18 substrate 20.3 min, (S)-product 15.6 min, (R)-product 15.9 min; 
entry 19 substrate 28.7min, (S)-product 24.7 min, (R)-product 25.0 min. 
Temperature program for 20: injector and detector temperature at 200 °C; split 
ratio 25:1; starting at 40 °C, hold 2 min, 20 °C.min
-1
 to 180 °C, hold 5 min. Retention 
time: substrate 10.4 min, product 11.1 min. Enantioselectivity of 24 was determined 
with HPLC equipped with Chiralcel OD-H column (25 cm, 0.46 cm, Daicel 
Chemical), with 60 min running buffer of n-heptane / isopropanol 95:5 (isocratic) set 
at 1 mL/min 18°C. Retention time: substrate 15.0 min, (R)-product 31.5 min, (S)-
product 34.30 min. 
Temperature program for 21: injector and detector temperature at 210°C; split 
ratio 6.4:1; starting at 80°C, 2.5°C.min
-1
 to 130°C, hold 10 min, 20°C.min
-1
 to 180°C, 
hold 2 min. Retention time: substrate 17.4 min and 19.8 min, (R)-product 12.2 min, 
(S)-product 12.4 min. 
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COMPUTATIONAL PROTEIN ENGINEERING OF YERSER WITH 
PRINCIPAL COMPONENT ANALYSIS 
6.1. Introduction 
 Enzymes are highly versatile and proficient catalysts. The ideal biocatalyst can 
greatly accelerate chemical reactions, combined with high substrate specificity, as well as 
exquisite enantioselectivity and stereoselectivity. Recent advances in the development of 
both experimental and computational protein engineering tools have enabled 
improvements in biocatalyst for better large-scale industrial applications.[1] Over the past 
two decades, directed evolution has transformed the field of protein engineering with an 
iterative two-step protocol, first creating molecular diversity by random mutagenesis and 
in vitro recombination, then followed by identifying library members of improved 
enzyme functions with established high-throughput screening method.[2] Alternative 
rational library design combines structural, mechanistic, and sequence-based knowledge 
to further enable new routes for smaller and more efficient library design. Another 
promising area employed computational engineering strategies as tools to evaluate 
protein sequence data and analyze the possible conformational variation within proteins 
allowing for novel enzyme function design.[3] These tools have enabled numerous 
improved biocatalysts, especially for the application in the field of pharmaceutical 
industry.  Examples are (R)-transaminase for the synthesis of active pharmaceutical 
ingredients of sitagliptin (Januvia® ), and ketoreductases, glucose dehydrogenase, and 
haloalkane dehalogenases for the synthesis of intermediate toward atorvastatin (Lipitor® ) 




6.1.1. Sequence-based enzyme engineering 
 Evolutionary information from protein sequences was studied in order to 
effectively navigate and identify the functionalities in protein sequence space. Tools such 
as multiple sequence alignments and phylogenetic analysis have become standard 
analysis for the exploration of amino acid relationships among groups of homologous 
protein sequence and structures. The exploited data were valued for functional 
identification such as enzyme hot spots, local amino acid variability, and as guide for 
possible back-to-consensus designs.[4, 5]    
 Examples of sequence-based data analysis tools include The HotSpot Wizard and 
3DM database. The HotSpot Wizard combines protein functionality data from sequence 
library and structure database to create a mutability map for target protein.[6] Similarly, 
3DM database integrates protein sequence and structure data from GeneBank and the 
PDB to produce protein superfamily alignments.[7] These tools collect protein 
functionality data effectively through a series of built-in filters to identify evolutionary 
features such as correlated mutations and amino acid conservation, and in return provided 
information on the functional role of individual amino acid residues including possible 
mutability for enzyme improvement.   
6.1.2. Structure-based enzyme engineering 
 Structure-based methods probe protein function linked to three dimensional 
structures by making mutations of one or more amino acids in the macromolecules 
sequence to cause a change in structural topology. The method is rendered possible by 
the rapidly growing number of protein structures in the PDB along with developments in 
homology modeling, rendering structure-based analogy a valuable additional tool for 
protein engineers to pinpoint key residues more effectively in active sites and design 
more efficient libraries. One of the examples using structural based method is structural-
guided consensus, which combines sequence-based and structural data and employs a set 
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of phylogenetically diverse but functionally proven proteins.[8, 9] Smaller library size 
can be further achieved via structural criteria such as distance to active site, addition of 
helix stabilizer, and salt-bridge formation. The conditions resulted in highly constrained 
mutational space and improve the percentage of positive hits within a library.      
6.1.3. Computationally-based enzyme engineering 
 The third wave of protein engineering is data-driven protein engineering [10]. By 
using available data in the form of structures and sequences to limit the library size, at the 
same time improving the chances of a „hit‟ through computational algorithm design. 
Advances in computational protein design algorithms have made modeling a highly 
promising strategy for redesign of biocatalysts. Together with the aid of evolutionary 
information as a guide for sequence alterations and combinatorial library preparation, 
computational strategies calculate amino acid variations on the overall protein structure, 
and greatly reduce the library size to a handful of rational designs. A more recent data-
driven approach is that involving advanced statistical methods (or machine learning) [11]. 
Machine learning and multivariate statistical methods can help identify hidden patterns in 
sequence-activity relationships and accelerate enzyme improvement. The requirements 
for the number of variants to be screened is also potentially low [12]. Thus, in situations 
where a high-throughput screening assay condition may not be a good choice for 
selecting improved variants, then due to time and resource constraints we can test only a 
selected set of mutants for activities in the actual process conditions (Fig 6.1) 
 
Figure 6.1. Overview of computational based protein engineering. 
  
WT 
Create initial set of variants 
Build model to predict functionality 
Introduce mutations 
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 Some recent works that have shown how statistical methods can be incorporated 
into protein engineering to improve upon enzyme functionality include: ProSAR (Protein 
Structure Activity Relationship) using partial least squares regression [13], probabilistic 
model developed specifically for protein systems [14-16], „Mt. Fuji‟ type landscape 
model [17, 18], and usage of multiple regression methods [19]. One of the major 
bottlenecks for almost all protein engineering methods is the selection and generation of 
the initial set of mutants. Even some of the above-mentioned statistical methods, for 
which this step serves to provide the initial data set for model building, use directed 
evolution to create the first set of mutants. Under conditions of low throughput assays 
however, this may not be desirable. In spite of all the protein engineering efforts so far, 
systematic methods for identifying target mutations a priori to any experimental work 
remain elusive. Examples of published techniques that have shown promise include 
SCHEMA [20], Rosetta [21], and CASTing [22]. 
 
6.2 Principal Component Analysis 
 In this work, a data-driven method to identify target positions and residues for 
mutations is presented. The idea is to identify patterns in a protein family‟s sequences, 
and locate possible changes (mutations) in the targeted protein of interest such that the 
new variant is closer to the underlying low dimensional manifold of the sequences. This 
low dimensional topology is identified by subjecting the protein family sequences to 
principal component analysis (PCA). Figure 6.2 below, shows the overall approach for 




Figure 6.2. Computational protein engineering with principal component analysis.  
 
 Principal component analysis general approach includes: (Step 1) Collect protein 
sequences from PDB, and align them with an alignment tool available such as ClustalW. 
To represent the sequences mathematically, we assign 20 dimensions to each position 
(corresponding to each amino acid), which are all zero expect for the amino acid residue 
present at that position (which will be assigned a value of unity). (Step 2) Subject the 
sequence data set to PCA, and reconstruct the protein sequence of interest with a limited 
number of principal components. For the i
th
 position, in the original data matrix we had a 
20 dimensional array – [0 0 0 0 …. 1 0 0 0] where there is a 1 for the residue present at 
that position and 0 otherwise. In the reconstructed matrix, this may not be the case: [0 0 0 
0 …. 0.3 0.45 0.25 0]. The value highest in magnitude (closest to 1) is then rounded off to 
1 and others to 0 to approximate the residue present in the reconstructed array. This 
number is the weighting; in the above example the weighting is 0.45. Positions that upon 
reconstruction have a residue different than the one present originally are the positions of 
interest for mutating, and the suggested residues from the PCA is the target residue. (Step 
3) Repeat the PCA and sequence mapping (reconstruction) with different data sets of the 
Identify lower dimensional 
topology
Map back to the sequence 
space
Approximate with points in 
lower dimensional space
Rank the WT mutations by 
repeating with different subsets 
and observing their frequency
Obtain sequences from 
protein data bank
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collected sequences, and rank the mutations based on the weight of the suggested residue 
and its frequency of occurrence. Gaps are excluded when considering mutations. 
 There are two parameters that the user has to define: (1) Window sizes: As stated 
above, different sub-sets of the sequences are used to identify mutations. The reason for 
this is to avoid biasing of the suggested residue by the closest homologues. Therefore, our 
protein of interest (say, protein number 1), is selected with (say) n other proteins from the 
sequences. This sub set then cascades down by one in the table, and so on. The number n 
is the window size. This procedure can be repeated with multiple window sizes, the range 
of which is up to the user. To test for variance in the mutations, any two sequences can be 
swapped to repeat the PCA. (2) Percentage cut-off for excluding positions having gaps: 
Upon alignment, there will be some positions having gaps in many of the sequences. 
These positions are considered as having no residue, or in mathematical terms, having 
lack of information for the data set. To avoid biasing the results from these positions with 
lack of information, only those positions with a certain percentage of information are 
included in the PCA. The cut-off is to be set by the user. The number of principal 
components can also be set as a parameter, but we suggest that these be varied from 1 to 
the maximum number (in this work, it will be the number of data points/sequences). The 
parameters used in the current analysis were set as: window size – varied from 16 to 24 in 
steps of 2, cut-off – 70%. 
 The PCA method was applied to the Old Yellow Enzyme family for validation. 
YersER from Yersinia bercovieri was used as model enzyme to mutation changes. In 
previous works, YersER showed broad ER specificity and broad temperature and pH 
optima but different specificity patterns; with strong cofactor preference for NADPH as 
over NADH and are stable up to 40 
o
C.[23] YersER also asymmetrically reduced a 
series of alkenes with moderate to excellent degree of stereoselectivity, where both 
substrate- and enzyme-based stereocontrol were observed to furnish opposite 
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stereoisomeric products (Chapter 5). All the above traits render YersER a potentially 
interesting enzyme for improvement with PCA analysis. 
The protein sequence data, expressed as given below, was subject to principal component 
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where n is the number of sequences = 28 for the OYE family, p is the number of 
dimensions = (....)20*number of positions in alignment. 
 To find the principal components (vectors in the n dimensional space along which 
the data might be concentrated), singular value decomposition (SVD) of the Z matrix 
(given below) has to be done. The Z matrix is obtained by mean centering the columns 
and making them of unit variance: 
1p11 1 12 2
1 2
T
npn1 1 n2 2
1 2
x xx -x x -x
  ........
.
Z  = 
.




















1x  and s1 are the mean and standard deviation of the first column in X
T
 and so on. 
SVD of the Z matrix will give the principal components through: 
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   
's are the singular values. 
The relatively larger values of 's will tell what the principal components are (the 
corresponding column vectors in U). The transformation of Z in the direction of the 
principal components is given by: 
T T
tf L L LZ  = U Z = S V  
where L denotes that we have taken only the first L principal 's . 
 As there were many columns with zeros, the columns were not normalized with 
the standard deviation. Also, one of the reasons for standard deviation normalization is to 
make the variables dimensionless. However, since the protein sequences expressed 
mathematically are of the same dimension, standard deviation normalization is not 
required. 
6.3 Results & Discussion 
6.3.1. Suggested YersER mutation from PCA  
 As the PCA aligned the sequences of known Old Yellow Enzyme sequences, the 
analysis suggested total of 133 mutants for YersER (Table 6.1). The mutants were ranked 
according to the averaged importance compared to the phylogenetic tree. In order to 
further reduce the library size, structural analysis were used to identify the possible “hot-
spots” among the 133 suggested mutations. Crystal structure of PETN reductase (PDB 
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2ABA), who shared 76% and 85% amino acid identity and similarity with YersER were 
used.[25]  The OYE family catalyzes reduction of activated alkenes through a two-step 
process: oxidation of cofactor by hydride transfer to the FMN cofactor (reductive half 
reaction), followed by the reduction of activated alkenes by hydride transfer from the 
reduced flavin (oxidative half reaction).[26, 27] The importance of FMN in catalytic 
pocket of OYEs greatly affects the enzyme efficiency in the reduction process, which 
becomes the center focus of targeted mutations. The crystal structure PDB 2ABA was 
analyzed centralized at the FMN ligand in the crystal structure and by setting the first- 
and second-shell residues within 4 Ǻ and 8 Ǻ, the modeling result reduced the library size 
down to twelve suggested mutations, with two mutants located within first shelf related to 
FMN.     
 
Table 6.1. Suggested mutations of YersER from PCA analysis. 
Average rank WT Residue Position# Suggested residue 
1.6 S 329 A 
1.8 I 179 V 
3.4 M 193 L 
4.2 L 81 I 
6 S 227 G 
6.4 H 265 G 
8.2 T 212 A 
10.2 E 93 A 
13.2 Q 117 G 
14 E 248 P 
14.6 T 222 V 
14.8 I 161 V 
16.2 P 240 T 
17 T 168 A 
17 A 196 S 
18 Y 178 G 
18.4 D 259 E 
22.4 F 64 A 
22.8 L 75 I 
24.4 E 229 D 
25.2 G 348 P 
25.6 Q 89 A 
26 A 72 T 
28.4 Q 225 E 
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Table 6.1. Suggested mutations of YersER from PCA analysis continued. 
30.8 F 317 L 
31 I 231 V 
31 D 249 N 
31.6 N 246 D 
32.4 A 83 G 
33.4 I 235 L 
33.6 A 253 D 
34.8 I 126 L 
34.8 Q 250 E 
35.2 H 185 N 
35.8 T 133 S 
37.4 H 190 D 
37.4 T 215 L 
37.8 W 226 I 
37.8 I 318 A 
38.4 I 271 M 
38.4 Y 178 L 
39.8 T 215 V 
40 L 214 F 
44 A 90 G 
45.4 L 181 I 
47.2 L 238 I 
47.6 A 99 F 
47.6 I 235 V 
48 A 224 E 
49.2 N 242 Q 
50.6 E 345 P 
50.8 I 37 V 
50.8 V 134 L 
52.8 T 154 L 
53.6 A 289 K 
55 H 97 K 
58.2 T 77 S 
58.4 I 208 V 
59.8 T 350 S 
60 G 243 N 
60.2 I 258 A 
60.4 P 346 Q 
60.6 D 347 R 
62 T 57 S 
64 K 295 H 
64.8 T 132 V 
65.4 Q 250 P 
65.4 E 155 D 
65.8 E 153 T 
67 A 183 S 
67.8 V 334 P 
69.2 D 245 G 
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Table 6.1. Suggested mutations of YersER from PCA analysis continued. 
 
72 V 105 T 
74 H 76 Y 
75.2 L 189 I 
76.8 D 288 E 
78.4 E 314 G 
81 D 288 Q 
82.4 I 108 V 
83 I 266 L 
83 A 303 R 
83.6 L 244 T 
83.6 E 311 D 
86.6 T 168 V 
87.2 D 129 N 
89 F 64 P 
89.8 N 262 G 
92 Q 203 E 
92.8 E 79 A 
97.2 E 156 D 
97.2 G 71 D 
98.4 S 194 R 
99.4 L 312 A 
99.8 A 253 T 
100 A 253 L 
101.2 G 279 D 
102.6 I 233 V 
104.2 R 131 K 
104.4 T 133 F 
106.2 A 127 K 
107 H 76 W 
107 P 195 S 
110.2 E 260 Q 
111.6 S 111 P 
111.8 E 310 N 
112.2 R 172 M 
112.2 Q 89 E 
114.6 G 348 A 
116 F 317 K 
117 A 128 I 
118.2 R 172 I 
118.2 E 94 A 
118.8 G 239 A 
122 E 155 A 
122.4 Q 89 D 
122.6 L 337 F 
122.8 F 164 Y 
125 L 244 M 
127.8 R 293 V 
127.8 E 94 K 
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Table 6.1. Suggested mutations of YersER from PCA analysis continued. 
 
128 I 313 L 
128.8 E 248 S 
129.2 A 70 P 
131.8 S 283 P 
133.8 A 277 I 
138.2 A 183 G 
139.6 D 249 E 
140.2 T 305 D 
141 A 320 L 
142.2 R 135 V 
144.4 P 346 Y 
157.4 E 229 G 
161 T 212 C 
 
6.3.2. YersER mutants activity and stereoselectivity study 
Total of 12 mutants were analyzed and compared with regard to wild type 
YersER activity for substrates of 2-cyclohexen-1-one and ketoisophorone (Table 6.2).  
The specific activity study showed 5 improved activity for mutants of I235L, T350S, 
T57S, A183S, and T350D; with improvement as high as 159.8% for reduction of 2-
cyclohexen-1-one with A183S variant. 4 mutants (G348P, I271M, A3030R, and P346Y) 
showed comparable specific activity with the wild-type YersER, with activity difference 
of < 10%. Only 3 mutants showed decreased in specific activity: A72T, H185N, and 
L181I; especially variant H185N appeared to lose all the activity.   
The mutants were also studied for possible change in stereoselectivity and nitro 
reductase activity with substrates of ketoisophorone, 1-nitro-2-phenylpropene, citral, and 
nitrobenzene (Table 6.3). However, no significant stereoselectivity difference was 
observed, and all mutants showed to be non-active with aromatic nitro substrate. This is 
possibly because the residue selections were focused on the FMN as localized center, 
which differences in catalytic hydride transfer between FMN and substrate were 
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expected, but no substrate flipping being forced in the binding pocket as the result of 
these mutations.  
Table 6.2. Specific activity study of YersER mutants. 
Avg Rank Mutant Specific Activity [U/mg]  
  2-cyclohexen1-one Ketoisophorone 
 WT 2.76 - 5.95 - 
25.2 G348P 2.53 91.7% 5.87 98.6% 
26 A72T 0.49 17.8% 1.28 21.5% 
33.4 I235L 3.70 134.1% 7.14 120.0% 
35.2 H185N 0.05 1.8% 0.18 3.0% 
38.4 I271M 2.72 98.6% 4.80 80.7% 
45.4 L181I 1.98 71.7% 4.41 74.1% 
59.8 T350S 4.04 146.4% 7.70 129.4% 
62 T57S 5.03 182.3% 8.42 141.5% 
67 A183S 4.41 159.8% 8.42 141.5% 
83 A303R 2.82 102.2% 6.73 113.1% 
140.2 T305D 3.87 140.2% 9.11 153.1% 
144.4 P346Y 2.61 94.6% 5.38 90.4% 
 







  Conv  e.e. % Conv  e.e. % Conv  e.e. % Conv  
 WT 96.3 (S) 5.8 39.6 (R) 98 96.0 (S) 99 - 
25.2 G348P 97.1 (S) 2.1 34.7 (R) 99 55.4 (S) 99 - 
26 A72T 92.7 (R) 7.3 21.1 (R) 99 36.0 (S) 99 - 
33.4 I235L 97.7 (S) 2.1 39.9 (R) 99 98.6 (S) 99 - 
35.2 H185N 15.4 (R) 15.3 24.7 (R) 99 41.6 (S) 99 - 
38.4 I271M 99.1 racemic 27.7 (R) 99 62.1 (S) 99 - 
45.4 L181I 42.3 (S) 6.9 27.7 (R) 99 89.2 (S) 99 - 
59.8 T350S 97.7 racemic 25.9 (R) 99 23.7 (S) 99 - 
62 T57S 97.8 racemic 22.1 (R) 99 65.6 (S) 99 - 
67 A183S 48.8 (S) 2.4 36.3 (R) 99 87.7 (S) 99 - 
83 A303R 98.8 (S) 1.5 43.3 (R) 99 78.7 (S) 99 - 
140.2 T305D 58.7 (S) 5.5 49.7 (R) 99 18.8 (S) 99 - 
144.4 P346Y 88.5 (S) 2.0 53.6 (R) 99 94.9 (S) 99 - 
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6.3.3. Chemical TTN study 
The total turnover number (TTN) is an indicator of lifetime biocatalyst 
productivity and is defined as the maximum number of molecules of substrate that an 
enzyme active site can convert over its life cycle. The chemical TTN (TTN) [28, 29] was 
experimentally determined by measuring the maximum amount of substrate 2-
cyclohexenone and citral that can be reduced with a set amount of purified enzyme before 
the enzyme is chemically deactivated (Table 6.4). In this study, we found the inhibition 
effect of substrate 2-cyclohexenone with enzyme YersER, which the enzyme showed 
improvement TTN with substrate citral. Temperature doesn‟t seem to influence the 
chemical TTN much in this case as we did not observe significant improvement by 
lowering reaction temperatures to 25 
o
C. All twelve mutants were analyzed with citral as 
substrate for chemical TTN. Interestingly, the improvement in TTN only observed for 
mutants T350S, T57S, A303R, and T305D; which most of these mutants showed higher 
specific activity compared to the wild-type YersER (Table 6.5). However, the TTN of 
both YersER and KYE1 were both lower to be interesting for industrial application, 
which usually required biocatalyst to have TTN in the order of 10
4
. Future improvement 
in enzyme specific activity and TTN will be necessary to apply these enzymes in large 
scale reaction system.   
Table 6.4. YersER and KYE1 TTN comparison. 








YersER 2-cyclohexen-1-one 37 2808 1488 
  Citral 37 8230 1488 
  Citral 30 10083 13124 
  Citral 25 11201 - 
KYE1 2-cyclohexen-1-one 37 2827 210 
  Citral 37 1880 210 
  Citral 30 3670 1146 
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Table 6.5. YersER WT and mutant TTN study. 
Avg Rank YersER TTN 
- WT 8283 
25.2 G348P 7275 
26 A72T 802 
33.4 I235L 2927 
35.2 H185N 160 
38.4 I271M 4705 
45.4 L181I 3957 
59.8 T350S 11032 
62 T57S 14130 
67 A183S 5599 
83 A303R 10233 
140.2 T305D 9614 
144.4 P346Y 3199 
 
6.4 Conclusion 
In summary, computational protein design has fundamentally changed the way 
protein engineers can alter protein functions, however, the most efficient result only can 
be achieved with the complementary angle of both directed revolution and computational 
modeling. The PCA method incorporated both sequence alignments and structural 
analogy knowledge to produce suggested mutations at specific positions. The work in this 
chapter focused on the mutations suggested by PCA with localized center focus on the 
FMN, the catalytic center of YersER. Total twelve mutants were studied for improvement 
in specific activity, conversion efficiency, and stereoselectivity. The mutants showed 
positive improvement in specific activity with 5 out of 12 mutants demonstrated higher 
specific activity compared to wild type enzyme. However, no significant changes were 
observed for stereopreference. The future work will focus on altering enzyme 
stereoselectivity with localized PCA on residues that affect the orientation of substrate 
within enzyme binding pocket.  
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6.5 Materials & Methods 
6.5.1 YersER QuikChange®  mutagenesis protocol 
 The mutations on YersER were accomplished with the QuikChange®  
mutagenesis protocol with the following PCR primers design. The YersER gene from 
Yersinia bercovieri in pET27 vector was used as the template for mutations. Failsafe 
buffer J (EPICENTER
®
 Biotechnology, Madison, WI) was used in the standard PCR 
protocol with Pfu polymerase from New England Biolabs (Marlborough, MA). PCR 
assay: 25 µL of Failsafe buffer J, 125 ng YersER DNA plasmid template, 0.25 µM each 
of both forward and reverse primers, and sterile water to 50 µL in total volume. The 
mixed sample was first denatured at 98 °C for 5 minutes, supplemented with 1 µL of Pfu 
buffer, followed by denaturation at 98 °C for another 30 seconds. The annealing 
temperature was set at 55 °C for 1 minute, extension at 72 °C for 16 minutes, and 
repeated for total of 18 cycles. The final extension was set at 72 °C for 25 minutes, and 
finished with temperature hold at 4 °C. All mutants were sequenced with Eurofins MWG 
Operon (Birmingham, AL) service and transformed into E. coli BL21 strain for protein 
expression and purification. 
Table 6.6. YersER mutants design. 















6.5.2 Enzyme purification and bioconversion assay  
YersER genes starter culture consisted of 5 ml LBKan, inoculated from frozen 
stock, and grown overnight at 37 °C. The starter culture was then used for inoculation of 
300 mL culture (0.1% v/v), which was gently aerated until OD600 reached 0.5 for addition 
of 0.1 mM IPTG and then left overnight for protein expression. Harvested cell pellets 
were kept for -80 °C for protein purification. The polyhistidine tagged enzymes were 
purified according to the standard Ni
2+
-NTA bead protocol from Qiagen (Valencia, CA).
 
The protein concentration was determined by the Bradford method with Coomassie Plus 
Protein assay reagent and BSA assay (Pierce Chemical, Chicago, IL) as the calibration 
curve. 
 The specific activity assays were performed with 200 mM phosphate buffer pH 
7.5, 10 mM substrate, 0.2 mM cofactor NADPH, and 10 μg.mL
-1
 enzyme. The 
conversion assay were performed with 200 mM phosphate buffer pH 7.5, 10 mM 
substrate, 20 µg.mL
-1
 (0.5 µM) enzyme, 0.2 mM NADP
+
, 20 mM glucose, 10 U.mL
-1
 
GDH, at room temperature incubated over 12 hours. Then an equal volume of ethyl 
acetate was added for extraction before analysis with GC. 
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CONCLUSION & FUTURE PERSPECTIVES 
 
 Asymmetric synthesis with biocatalysts has become an increasingly interesting 
and cost-effective manufacturing option in fine chemicals, pharmaceuticals, and 
agrochemical intermediates. Ene reductases from the Old Yellow Enzyme family offer 
high substrate efficiency, regio-, stereo-, and enantiomeric selectivity in the catalyzed 
biotransformations. Asymmetric reduction of activated C=C bond is one of the most 
widely applied synthetic tools for the potential to generate up to two stereogenic centers 
in a one-step reaction. Current existing synthetic methods of asymmetric hydrogenation 
involve the use of precious metals in conjunction with chiral phosphines as well as 
organocatalytic hydrogenation of cyclic enones to allow a wider choice of substrates and 
products. However, the addition of biocatalytic hydrogenation of activated alkenes has 
proven to be highly effective to produce enantiomerically pure compounds and has 
become an additional precious tool for both the established synthetic pathways and novel 
methods.    
 The thesis contributed to the enzymes development and characterization of the 
Old Yellow Enzyme family with regards to addition of new chemistry such as 
exploitation of nitroreductase activity with NRSal from Salmonella typhimurium, where 
we investigated the reduction of α,β-unsaturated carbonyl compounds, nitroalkenes, and 
nitroaromatics substrates.  We also reported the first single-isolated enzyme-catalyzed 
reduction of nitrobenzene to aniline through the formation of nitrosobenzene and 
phenylhydroxylamine as intermediates. The development and characterization of novel 
enzymes YersER from Yersinia bercovieri and KYE1 from Kluyveromyces lactis 
demonstrated that both enzymes have broad ene reductase specificity and are able to 
operate under broad temperature and pH optima but with different specificity patterns. 
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Both substrate- and enzyme-based stereocontrol were observed for both YersER and 
KYE1 to furnish opposite stereoisomeric products. Further improvement and 
characterization on XenA from Pseudomonas putida showed broad catalytic activity to 
reduce various α,β-unsaturated and nitro compounds with moderate to excellent 
stereoselectivity. Mutations C25G and C25V of XenA are able to reduce nitrobenzene, a 
non-active substrate for the wild type, to produce aniline. The combination of 
computational protein engineering in form of the method of Principal Component 
Analysis together with structure-guided consensus enabled the improvement of YersER, 
where significant improvements of specific activity were detected. Lastly, the work also 
contributed towards larger-scale system preparation by investigating enzyme stability and 
organic solvent behavior. We studied the total turnover number (TTN) as an indicator of 
lifetime biocatalyst productivity for YersER, KYE1, and XenA. The TTN of XenA 
proved to be dominated by chemical rather than thermal instability. The effects of organic 
solvents on enzyme activity and stereoselectivity were tested with YersER and KYE1 to 
show the sustainable bioreduction efficiency even at high organic solvent content. Future 
work will concentrate on enabling of a sustainable and stable scale-up system to 
demonstrate the possible applications of these enzymes. 
 The field of Old Yellow Enzyme has evolved in the past few decades. Starting 
with the discovery of new enzymes and initial characterization for enzyme activity in the 
1980s – 1990s, in the 2000s, more groups have focused efforts on enzyme selectivity 
studies together with the biochemistry of the discovered ene reductases. Numerous 
enzymes such as OYE from Saccharomyces carlsbergensis, OYE2-3 from 
Saccharomyces cerevisiae, KYE1 from Kluyveromyces lactis, OYE from Candida 
macedoniensis, YqjM from Bacillus subtilis, YersER from Yersinia bercovieri, PETN 
reductase from Enterobacter cloacae, OPR1 and OPR3 from Arabidopsis thaliana, have 
been thoroughly studied and characterized in term of its chemo-, regio-, and 
stereoselectivity. A few groups have also contributed to the search of key residues within 
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OYE family. Given the vast developments in all these fields, the immediate future 
perspectives focus on the possible enzyme engineering of OYE family members for 
altered substrate specificity and better stereocontrol of final product, together with 
reaction scale-up research for actual industrial applications in the near future.  
 The thesis contributions highlighted above have added valuable insights into all 
the recent development efforts within ene reductases. The enzymes characterization 
results shown in Chapter 2 – 5, together with published works on other OYE candidates, 
have mapped out the sequence substrate relationship within the OYE family. Based on 
these findings, the community will able to categorize enzymes into strong ene reductases, 
bi functional enzymes of ene and nitro reductases, and strong nitroreductases, all of 
which showed a favorable set of substrate range and stereochemistry in the 
biotransformation. The work on PCA analysis on YersER (Chapter 6) showed the first 
initiation of computational protein engineering efforts within the OYE family. Current 
PCA analysis showed promising results with significant improvements observed for 
suggested mutants; however, further effort is currently in progress to enable the wide 
application of the PCA method on the protein engineering front. The PCA will focus on 
finding the key residues within the OYE family that controls the chemistry and 
stereoselectivity of these enzymes. By comparison of binding pocket residues across the 
whole OYE family, PCA will analyze the distinct differences among the amino acid 
residues and suggest possible mutations at each specific location. This effort will further 
the understanding of OYE’s biochemistry and improve upon better protein engineering in 
the future.  Enzyme stability with ene reductase is also a current issue for further scale up 
development. As we have discussed in both Chapter 4 and 5, ene reductase showed poor 
enzyme stability with low chemical TTN measured for all the tested enzymes (XenA, 
YersER, and KYE1). We foresee additional effort to improve upon the stability through 
possible enzyme engineering procedures before the actual large scale application of these 
OYE enzymes. A possible method will be to increase the enzyme activity through 
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mutations around enzyme FMN, as current initial result have suggested variants with 
improved specific activity have shown to yield higher chemical TTN compared with the 
wild type enzymes. These entire contributions center around the final goal to derive the 
sequence functionality relationship among these OYE enzymes, with better 
understanding about the key residues, achieve product stereocontrol, and develop stable 
enzyme variant. We are at the forefront of OYE engineering for better future applications 
of ene and nitro reductases.             
 
7.1 Future Perspectives 
 
7.1.1 Effects of organic solvents on catalytic efficiency and stereoselectivity  
 Processes with enzymatic conversions are advancing in the fields of food 
industry, fine chemical synthesis, pharmaceuticals, and even for environmental purposes. 
Traditional batch reactors with temperature control often required an enzyme deactivation 
step at the end of run before recovering final products. Although such a reactor system is 
relatively simple with control of only pH and temperature, it comes with several 
disadvantages such as low productivity, high operating cost, enzyme deactivation, and 
inconsistent product quality.[1]  To overcome the limitations of the batch reactor, the 
development of immobilized enzyme became popular in the 1970s. Various immobilized 
enzyme systems were proposed to localize the biological catalyst in a definite surface, 
which allowed for the preservation of enzymatic activity and reusability. However, 
immobilization of enzyme on carrier beads resulted in the loss of enzymatic activity as 
the active site of the enzyme was distorted during the immobilization process, and 
interfacial limitation at the surface prevent the diffusion of substrate towards the 
immobilized enzyme.[2] The introduction of membrane technology leads to a revolution 
in the immobilized enzyme technology.  
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 The enzyme membrane reactor (EMR) is a continuous stirred tank system in 
which enzymes are separated with the final products with the help of a selective 
membrane. Unlike the immobilized system, EMR allows either the enzyme molecules to 
circulate freely on the retentate side or immobilize onto the membrane surface by 
maintaining full activity inside the reactor. Dependent on the selectivity requirement for 
specific reaction, ultrafiltration membranes with molecular weight cut-off between 3 kDa 
and 100 kDa are available .[3] In the reported studies, enzyme membrane reactors 
successfully enhanced the productivity and practicality of bioconversions by increased 
the substrate / enzyme contact ratio, provided a simple and reversible platform for 
enzyme localization, and effectively removed both reaction products and possible 
inhibitory compounds.  
 In the industrial application of enzyme membrane system also increase due to the 
advancement in the multiphase reaction systems. The majority of the enzyme-catalyzed 
reactions took place in aqueous solutions, but many substrates of industrial interest 
exhibit very low water solubility. Although substrate solubility can be increased with 
addition of organic solvents in multiphase systems, there are mass-transfer limitations for 
the diffusion of low-water-soluble substrates and the separation and recovery of product 
is difficult. [4]   
 The use of whole-cell system with ene reductases was generally limited with 
carbonyl compounds by the presence of endogenous ketoreductases in the host cells, 
which also employ nicotinamide cofactors to reduce the carbonyl function. Although the 
reported stereoselectivity is often adequate, the chemoselectivity of whole-cell reduction 
with respect to C=C and C=O bonds is poor. Since the amount of cofactor is limited in 
the whole cell, there is a need to introduce cofactor regeneration into the system. The 
system designed to couple ene reductase with cofactor recycling system will consist of 
glucose dehydrogenase (GDH). Cofactor regeneration system is a key to the development 




, $10853/mol NADH, $13973/mol NADP
+
, and $205418/mol NADPH [5]), which 
prohibits their stoichiometric use and thus required a robust regeneration system.[6] 
Enzyme cofactor regeneration is performed by isolated enzymes in enzyme-coupled 
system. Two coupled enzymes, ene reductase and glucose dehydrogenase, will carry out 
two parallel redox reactions: substrate target biotransformation by ERs and cofactor 
recycling with auxiliary substrate. In the proposed scheme, GDH catalyzes the oxidation 
of glucose to gluconic acid with the concomitant reduction of NAD(P)
+
 to NAD(P)H.[7] 
 The future research may focus to set up a stable cofactor regeneration system 
without using an EMR or a whole-cell system. Isolated ene reductase candidates will be 
coupled with the GDH regeneration system. The ideal cofactor regeneration should show 
fast conversion of substrate with the minimum loading of GDH into the system without 
any side reactions. A thermostable GDH has been provided by Vazquez-Figueroa [8] 
with great stability showing half-life of 3.5 days at 65
o
C. Data comparison with different 
amount of GDH, ER, substrate of interest, and auxiliary substrate will suggest the most 
efficient system to generate chiral nitroalkanes with the highest possible enantiomeric 
excess, the highest biocatalyst productivity (both in terms of g product / g catalyst and of 
total turnover number), and volumetric productivity (space-time-yield). Possible 
inhibition effects of either enzyme will also be eliminated at this point for better reaction 
conversion. The established cofactor recycling method will then be transferred into the 
EMR system.  
 The EMR with continuous stirred tank system will be tested for enantiomer 
product synthesis. The EMR manufactured by Forschungszentrum Jülich consisted of a 2 
– 10 mL stainless steel, thermostatted vessel with one flat-sheet of membrane placed in 
the middle of the reactor stabilized by a supporting disk. The selected membrane will 
have a molecular weight cutoff of 3-10 kDa since most of the ene reductases have 
molecular weights ranging from 30 kDa to 60 kDa. The aqueous stream consisting of 
reactants, cofactor, and enzyme will be fed into the bottom part of the reactor, where a 
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magnetic stir bar is present to ensure the homogeneity of the system for efficient reactant 
to product conversion. The product formed then passes the UF membrane and is collected 
for further analysis. The membrane reactors will be optimized with respect to the 
following input variables: (1) enzyme loading, (2) pH, (3) temperature, (4) reaction 
volume, and (6) feed substrate concentration. The optimization process will be performed 
with one variable at a time, and then used the optimum value for next parameter 
optimization. The final product will be analyzed with regard to the enantiopurity, 
membrane reactor productivity, operational stability of the enzymes, and product yield. A 
successful system should provide ≥ 50% substrate conversion with product enantiopurity 
of ≥ 70%. Also, parameters such as enzyme total turnover number and space-time yield 
will be calculated to ensure satisfactory catalytic function of the enzyme.  
 The cofactor recycling system will also be coupled into the whole cell for in vitro 
application of ene reductase. The whole cell system will analyze the difference of 
conversion efficacy in: (1) one plasmid vs. two plasmid cloning, (2) resting vs. dead vs. 
growing cell system, (3) natural cell metabolism vs. with cloned GDH. Comparison 
between the EMR and whole cell systems will be calculated base on the system 
conversion efficiency for the reaction of interest, the enantiopurity of the final product, 
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